uuid,question,answer,source,Date,Responder 1,Response 2,Source,Date,Responder 2,Notes,Template Questions ,,
Q1,Is TUBB a druggable gene?,"There are currently 20 approved drugs which target TUBB, indicating that it is a druggable gene.  ","DrugGeneTargets_text_627
DrugGeneTargets_text_613
DrugGeneTargets_text_614
DrugGeneTargets_text_624
DrugGeneTargets_text_625
DrugGeneTargets_text_629
DrugGeneTargets_text_601
DrugGeneTargets_text_592
DrugGeneTargets_text_599
DrugGeneTargets_text_594
DrugGeneTargets_text_608
DrugGeneTargets_text_612
DrugGeneTargets_text_606
DrugGeneTargets_text_568
DrugGeneTargets_text_622
DrugGeneTargets_text_623
DrugGeneTargets_text_578
DrugGeneTargets_text_630
DrugGeneTargets_text_591
DrugGeneTargets_text_602
DrugGeneTargets_text_580",7/17/2024,Maya,,,,,,Is [approvedSymbol] a druggable gene?,"There are currently {number_of_approved_drugs} approved drugs which target {approvedSymbol}, indicating that it is a druggable gene.","There are currently no approved drugs targeting {approvedSymbol}, but there are {number_of_potential_targets (not approved yet)} potential targets indicating that it may be a druggable gene."
Q2,What are the allele frequencies of variant rs12206095 in PD?,"In the GWAS summary statistics for PD from Nalls (2019), single nucleotide polymorphism rs12206095 has an alternate allele (A) frequency of 0.0317, and a reference allele (G) frequency of 0.9683.",PDno23andme_full_gene_notext_198,7/22/2024,Maya,,,,,,What are the allele frequencies of variant x in y?,,
Q3,What are the allele frequencies of variant rs61769339 in AD?,"In GWAS summary statistics for AD from Bellenguez (2022), single nucleotide polymorphism rs61769339 has an alternate allele (A) frequency of 0.1105 and reference
allele (G) frequency of 0.8895.",AD_combo_gene_notext_UUID_7,7/22/2024,Maya,,,,,,,,
Q4,What drugs target the gene ACACA? ,"There are no FDA approved drugs targeting the gene ACACA. However the following drugs, Firsocostat
Pf-05175157, Clesacostat, and Olumacostat Glasaretil are currently in various clinical trial stages. ","DrugGeneTargets_text_11316
DrugGeneTargets_text_11314
DrugGeneTargets_text_11315
DrugGeneTargets_text_11313",7/22/2024,Maya,,,,,,What drugs target the gene x? ,,
Q5,Is Rotigotine approved to treat AD?,"Rotigotine has not been approved by the FDA as a treatment for Alzheimer's disease (AD), but it is currently undergoing evaluation in clinical trials for this purpose.","DrugTargetsIndication121923_text_201120
DrugTargetsIndication121923_text_200835
DrugTargetsIndication121923_text_201210
DrugTargetsIndication121923_text_201220
DrugTargetsIndication121923_text_200920
DrugTargetsIndication121923_text_201135
DrugTargetsIndication121923_text_201305
DrugTargetsIndication121923_text_200720
DrugTargetsIndication121923_text_200785
DrugTargetsIndication121923_text_201100
DrugTargetsIndication121923_text_201255
DrugTargetsIndication121923_text_200875
DrugTargetsIndication121923_text_200925
DrugTargetsIndication121923_text_200820
DrugTargetsIndication121923_text_200840
DrugTargetsIndication121923_text_201275
DrugTargetsIndication121923_text_201335
DrugTargetsIndication121923_text_200725
DrugTargetsIndication121923_text_200845
DrugTargetsIndication121923_text_200910
DrugTargetsIndication121923_text_201105
DrugTargetsIndication121923_text_200805
DrugTargetsIndication121923_text_200850
DrugTargetsIndication121923_text_200870
DrugTargetsIndication121923_text_200990
DrugTargetsIndication121923_text_201250
DrugTargetsIndication121923_text_200710
DrugTargetsIndication121923_text_200810
DrugTargetsIndication121923_text_201055
DrugTargetsIndication121923_text_201215
DrugTargetsIndication121923_text_201285
DrugTargetsIndication121923_text_200750
DrugTargetsIndication121923_text_201075
DrugTargetsIndication121923_text_200745
DrugTargetsIndication121923_text_200800
DrugTargetsIndication121923_text_200980
DrugTargetsIndication121923_text_201175
DrugTargetsIndication121923_text_200970
DrugTargetsIndication121923_text_201005
DrugTargetsIndication121923_text_201035
DrugTargetsIndication121923_text_201155
DrugTargetsIndication121923_text_201205
DrugTargetsIndication121923_text_201110
DrugTargetsIndication121923_text_201270
DrugTargetsIndication121923_text_200935
DrugTargetsIndication121923_text_200865
DrugTargetsIndication121923_text_201160
DrugTargetsIndication121923_text_201000
DrugTargetsIndication121923_text_201170
DrugTargetsIndication121923_text_201070
DrugTargetsIndication121923_text_201085
DrugTargetsIndication121923_text_201115
DrugTargetsIndication121923_text_201140
DrugTargetsIndication121923_text_201080
DrugTargetsIndication121923_text_200740
DrugTargetsIndication121923_text_200790
DrugTargetsIndication121923_text_200955
DrugTargetsIndication121923_text_201125
DrugTargetsIndication121923_text_200900
DrugTargetsIndication121923_text_200815
DrugTargetsIndication121923_text_200930
DrugTargetsIndication121923_text_200730
DrugTargetsIndication121923_text_200760
DrugTargetsIndication121923_text_201030
DrugTargetsIndication121923_text_201050
DrugTargetsIndication121923_text_200860
DrugTargetsIndication121923_text_200915
DrugTargetsIndication121923_text_201180
DrugTargetsIndication121923_text_201195
DrugTargetsIndication121923_text_201330
DrugTargetsIndication121923_text_200770
DrugTargetsIndication121923_text_200780
DrugTargetsIndication121923_text_200985
DrugTargetsIndication121923_text_201165
DrugTargetsIndication121923_text_201020
DrugTargetsIndication121923_text_201065
DrugTargetsIndication121923_text_201190
DrugTargetsIndication121923_text_200765
DrugTargetsIndication121923_text_201200
DrugTargetsIndication121923_text_200975
DrugTargetsIndication121923_text_201145
DrugTargetsIndication121923_text_201235
DrugTargetsIndication121923_text_201295
DrugTargetsIndication121923_text_200755
DrugTargetsIndication121923_text_201095
DrugTargetsIndication121923_text_200885
DrugTargetsIndication121923_text_200890
DrugTargetsIndication121923_text_201245
DrugTargetsIndication121923_text_200905
DrugTargetsIndication121923_text_201280
DrugTargetsIndication121923_text_201320
DrugTargetsIndication121923_text_200880
DrugTargetsIndication121923_text_200855
DrugTargetsIndication121923_text_200945
DrugTargetsIndication121923_text_200960
DrugTargetsIndication121923_text_200950
DrugTargetsIndication121923_text_201015
DrugTargetsIndication121923_text_201130
DrugTargetsIndication121923_text_200775
DrugTargetsIndication121923_text_201315
DrugTargetsIndication121923_text_200715
DrugTargetsIndication121923_text_200795
DrugTargetsIndication121923_text_201060
DrugTargetsIndication121923_text_201290
DrugTargetsIndication121923_text_200735
DrugTargetsIndication121923_text_201185
DrugTargetsIndication121923_text_201300
DrugTargetsIndication121923_text_200825
DrugTargetsIndication121923_text_200830
DrugTargetsIndication121923_text_200965
DrugTargetsIndication121923_text_201010
DrugTargetsIndication121923_text_201025
DrugTargetsIndication121923_text_201150
DrugTargetsIndication121923_text_201265
DrugTargetsIndication121923_text_201310
DrugTargetsIndication121923_text_201325
DrugTargetsIndication121923_text_200895
DrugTargetsIndication121923_text_201225
DrugTargetsIndication121923_text_201045
DrugTargetsIndication121923_text_201090
DrugTargetsIndication121923_text_201230
DrugTargetsIndication121923_text_201260
DrugTargetsIndication121923_text_201040
DrugTargetsIndication121923_text_200940
DrugTargetsIndication121923_text_200995
DrugTargetsIndication121923_text_201240",7/22/2024,Maya,,,,,,Is x approved to treat y?,,
Q6,What genes does Rotigotine target when it's used to treat AD?,"Rotigotine has not been approved by the FDA as a treatment for Alzheimer's disease (AD), but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene targets are DRD2, DRD3, and DRD4.","DrugTargetsIndication121923_text_201120
DrugTargetsIndication121923_text_200835
DrugTargetsIndication121923_text_201210
DrugTargetsIndication121923_text_201220
DrugTargetsIndication121923_text_200920
DrugTargetsIndication121923_text_201135
DrugTargetsIndication121923_text_201305
DrugTargetsIndication121923_text_200720
DrugTargetsIndication121923_text_200785
DrugTargetsIndication121923_text_201100
DrugTargetsIndication121923_text_201255
DrugTargetsIndication121923_text_200875
DrugTargetsIndication121923_text_200925
DrugTargetsIndication121923_text_200820
DrugTargetsIndication121923_text_200840
DrugTargetsIndication121923_text_201275
DrugTargetsIndication121923_text_201335
DrugTargetsIndication121923_text_200725
DrugTargetsIndication121923_text_200845
DrugTargetsIndication121923_text_200910
DrugTargetsIndication121923_text_201105
DrugTargetsIndication121923_text_200805
DrugTargetsIndication121923_text_200850
DrugTargetsIndication121923_text_200870
DrugTargetsIndication121923_text_200990
DrugTargetsIndication121923_text_201250
DrugTargetsIndication121923_text_200710
DrugTargetsIndication121923_text_200810
DrugTargetsIndication121923_text_201055
DrugTargetsIndication121923_text_201215
DrugTargetsIndication121923_text_201285
DrugTargetsIndication121923_text_200750
DrugTargetsIndication121923_text_201075
DrugTargetsIndication121923_text_200745
DrugTargetsIndication121923_text_200800
DrugTargetsIndication121923_text_200980
DrugTargetsIndication121923_text_201175
DrugTargetsIndication121923_text_200970
DrugTargetsIndication121923_text_201005
DrugTargetsIndication121923_text_201035
DrugTargetsIndication121923_text_201155
DrugTargetsIndication121923_text_201205
DrugTargetsIndication121923_text_201110
DrugTargetsIndication121923_text_201270
DrugTargetsIndication121923_text_200935
DrugTargetsIndication121923_text_200865
DrugTargetsIndication121923_text_201160
DrugTargetsIndication121923_text_201000
DrugTargetsIndication121923_text_201170
DrugTargetsIndication121923_text_201070
DrugTargetsIndication121923_text_201085
DrugTargetsIndication121923_text_201115
DrugTargetsIndication121923_text_201140
DrugTargetsIndication121923_text_201080
DrugTargetsIndication121923_text_200740
DrugTargetsIndication121923_text_200790
DrugTargetsIndication121923_text_200955
DrugTargetsIndication121923_text_201125
DrugTargetsIndication121923_text_200900
DrugTargetsIndication121923_text_200815
DrugTargetsIndication121923_text_200930
DrugTargetsIndication121923_text_200730
DrugTargetsIndication121923_text_200760
DrugTargetsIndication121923_text_201030
DrugTargetsIndication121923_text_201050
DrugTargetsIndication121923_text_200860
DrugTargetsIndication121923_text_200915
DrugTargetsIndication121923_text_201180
DrugTargetsIndication121923_text_201195
DrugTargetsIndication121923_text_201330
DrugTargetsIndication121923_text_200770
DrugTargetsIndication121923_text_200780
DrugTargetsIndication121923_text_200985
DrugTargetsIndication121923_text_201165
DrugTargetsIndication121923_text_201020
DrugTargetsIndication121923_text_201065
DrugTargetsIndication121923_text_201190
DrugTargetsIndication121923_text_200765
DrugTargetsIndication121923_text_201200
DrugTargetsIndication121923_text_200975
DrugTargetsIndication121923_text_201145
DrugTargetsIndication121923_text_201235
DrugTargetsIndication121923_text_201295
DrugTargetsIndication121923_text_200755
DrugTargetsIndication121923_text_201095
DrugTargetsIndication121923_text_200885
DrugTargetsIndication121923_text_200890
DrugTargetsIndication121923_text_201245
DrugTargetsIndication121923_text_200905
DrugTargetsIndication121923_text_201280
DrugTargetsIndication121923_text_201320
DrugTargetsIndication121923_text_200880
DrugTargetsIndication121923_text_200855
DrugTargetsIndication121923_text_200945
DrugTargetsIndication121923_text_200960
DrugTargetsIndication121923_text_200950
DrugTargetsIndication121923_text_201015
DrugTargetsIndication121923_text_201130
DrugTargetsIndication121923_text_200775
DrugTargetsIndication121923_text_201315
DrugTargetsIndication121923_text_200715
DrugTargetsIndication121923_text_200795
DrugTargetsIndication121923_text_201060
DrugTargetsIndication121923_text_201290
DrugTargetsIndication121923_text_200735
DrugTargetsIndication121923_text_201185
DrugTargetsIndication121923_text_201300
DrugTargetsIndication121923_text_200825
DrugTargetsIndication121923_text_200830
DrugTargetsIndication121923_text_200965
DrugTargetsIndication121923_text_201010
DrugTargetsIndication121923_text_201025
DrugTargetsIndication121923_text_201150
DrugTargetsIndication121923_text_201265
DrugTargetsIndication121923_text_201310
DrugTargetsIndication121923_text_201325
DrugTargetsIndication121923_text_200895
DrugTargetsIndication121923_text_201225
DrugTargetsIndication121923_text_201045
DrugTargetsIndication121923_text_201090
DrugTargetsIndication121923_text_201230
DrugTargetsIndication121923_text_201260
DrugTargetsIndication121923_text_201040
DrugTargetsIndication121923_text_200940
DrugTargetsIndication121923_text_200995
DrugTargetsIndication121923_text_201240",7/22/2024,Maya,,,,,,What genes does x target when it's used to treat y?,,
Q7,What are the approved uses for Rotigotine?,Rotigotine has been approved to treat Parkinson Disease and Restless Legs Syndrome. ,"DrugTargetsIndication121923_text_200751
DrugTargetsIndication121923_text_200846
DrugTargetsIndication121923_text_200941
DrugTargetsIndication121923_text_200976
DrugTargetsIndication121923_text_201012
DrugTargetsIndication121923_text_201071
DrugTargetsIndication121923_text_201182
DrugTargetsIndication121923_text_201262
DrugTargetsIndication121923_text_201322
DrugTargetsIndication121923_text_200822
DrugTargetsIndication121923_text_200876
DrugTargetsIndication121923_text_200892
DrugTargetsIndication121923_text_201006
DrugTargetsIndication121923_text_201117
DrugTargetsIndication121923_text_201167
DrugTargetsIndication121923_text_201001
DrugTargetsIndication121923_text_201062
DrugTargetsIndication121923_text_201122
DrugTargetsIndication121923_text_201276
DrugTargetsIndication121923_text_201326
DrugTargetsIndication121923_text_200817
DrugTargetsIndication121923_text_200907
DrugTargetsIndication121923_text_201042
DrugTargetsIndication121923_text_201172
DrugTargetsIndication121923_text_201211
DrugTargetsIndication121923_text_201301
DrugTargetsIndication121923_text_201327
DrugTargetsIndication121923_text_200961
DrugTargetsIndication121923_text_201027
DrugTargetsIndication121923_text_201061
DrugTargetsIndication121923_text_201212
DrugTargetsIndication121923_text_201246
DrugTargetsIndication121923_text_201256
DrugTargetsIndication121923_text_201267
DrugTargetsIndication121923_text_201332
DrugTargetsIndication121923_text_200726
DrugTargetsIndication121923_text_200826
DrugTargetsIndication121923_text_200827
DrugTargetsIndication121923_text_200867
DrugTargetsIndication121923_text_200922
DrugTargetsIndication121923_text_200946
DrugTargetsIndication121923_text_200986
DrugTargetsIndication121923_text_200987
DrugTargetsIndication121923_text_200992
DrugTargetsIndication121923_text_201101
DrugTargetsIndication121923_text_200757
DrugTargetsIndication121923_text_200956
DrugTargetsIndication121923_text_201136
DrugTargetsIndication121923_text_201331
DrugTargetsIndication121923_text_200916
DrugTargetsIndication121923_text_201076
DrugTargetsIndication121923_text_200902
DrugTargetsIndication121923_text_200971
DrugTargetsIndication121923_text_201011
DrugTargetsIndication121923_text_201077
DrugTargetsIndication121923_text_201191
DrugTargetsIndication121923_text_201192
DrugTargetsIndication121923_text_201197
DrugTargetsIndication121923_text_201307
DrugTargetsIndication121923_text_200742
DrugTargetsIndication121923_text_200837
DrugTargetsIndication121923_text_200882
DrugTargetsIndication121923_text_200932
DrugTargetsIndication121923_text_200712
DrugTargetsIndication121923_text_200771
DrugTargetsIndication121923_text_201052
DrugTargetsIndication121923_text_201111
DrugTargetsIndication121923_text_201271
DrugTargetsIndication121923_text_200816
DrugTargetsIndication121923_text_200852
DrugTargetsIndication121923_text_200936
DrugTargetsIndication121923_text_201296
DrugTargetsIndication121923_text_200807
DrugTargetsIndication121923_text_200861
DrugTargetsIndication121923_text_200951
DrugTargetsIndication121923_text_201137
DrugTargetsIndication121923_text_201232
DrugTargetsIndication121923_text_200906
DrugTargetsIndication121923_text_200996
DrugTargetsIndication121923_text_201017
DrugTargetsIndication121923_text_201142
DrugTargetsIndication121923_text_201151
DrugTargetsIndication121923_text_201171
DrugTargetsIndication121923_text_200766
DrugTargetsIndication121923_text_200811
DrugTargetsIndication121923_text_200912
DrugTargetsIndication121923_text_201187
DrugTargetsIndication121923_text_201226
DrugTargetsIndication121923_text_200787
DrugTargetsIndication121923_text_200791
DrugTargetsIndication121923_text_200981
DrugTargetsIndication121923_text_201156
DrugTargetsIndication121923_text_201247
DrugTargetsIndication121923_text_201266
DrugTargetsIndication121923_text_201277
DrugTargetsIndication121923_text_200871
DrugTargetsIndication121923_text_201121
DrugTargetsIndication121923_text_201181
DrugTargetsIndication121923_text_201217
DrugTargetsIndication121923_text_201306
DrugTargetsIndication121923_text_200842
DrugTargetsIndication121923_text_200851
DrugTargetsIndication121923_text_200957
DrugTargetsIndication121923_text_200991
DrugTargetsIndication121923_text_201066
DrugTargetsIndication121923_text_201157
DrugTargetsIndication121923_text_201207
DrugTargetsIndication121923_text_200722
DrugTargetsIndication121923_text_200952
DrugTargetsIndication121923_text_200977
DrugTargetsIndication121923_text_201152
DrugTargetsIndication121923_text_201176
DrugTargetsIndication121923_text_201291
DrugTargetsIndication121923_text_201292
DrugTargetsIndication121923_text_200746
DrugTargetsIndication121923_text_200862
DrugTargetsIndication121923_text_200891
DrugTargetsIndication121923_text_201051
DrugTargetsIndication121923_text_201126
DrugTargetsIndication121923_text_200792
DrugTargetsIndication121923_text_201082
DrugTargetsIndication121923_text_201201
DrugTargetsIndication121923_text_201216
DrugTargetsIndication121923_text_200772
DrugTargetsIndication121923_text_201007
DrugTargetsIndication121923_text_201047
DrugTargetsIndication121923_text_201067
DrugTargetsIndication121923_text_201096
DrugTargetsIndication121923_text_201106
DrugTargetsIndication121923_text_201131
DrugTargetsIndication121923_text_201161
DrugTargetsIndication121923_text_201086
DrugTargetsIndication121923_text_201227
DrugTargetsIndication121923_text_201286
DrugTargetsIndication121923_text_200777
DrugTargetsIndication121923_text_200927
DrugTargetsIndication121923_text_200801
DrugTargetsIndication121923_text_200806
DrugTargetsIndication121923_text_200836
DrugTargetsIndication121923_text_200931
DrugTargetsIndication121923_text_200782
DrugTargetsIndication121923_text_200942
DrugTargetsIndication121923_text_201166
DrugTargetsIndication121923_text_200901
DrugTargetsIndication121923_text_200967
DrugTargetsIndication121923_text_201021
DrugTargetsIndication121923_text_201162
DrugTargetsIndication121923_text_200711
DrugTargetsIndication121923_text_200721
DrugTargetsIndication121923_text_200736
DrugTargetsIndication121923_text_201321
DrugTargetsIndication121923_text_200747
DrugTargetsIndication121923_text_200781
DrugTargetsIndication121923_text_200856
DrugTargetsIndication121923_text_200897
DrugTargetsIndication121923_text_200972
DrugTargetsIndication121923_text_201026
DrugTargetsIndication121923_text_201072
DrugTargetsIndication121923_text_201177
DrugTargetsIndication121923_text_201231
DrugTargetsIndication121923_text_200717
DrugTargetsIndication121923_text_200796
DrugTargetsIndication121923_text_200812
DrugTargetsIndication121923_text_201036
DrugTargetsIndication121923_text_201206
DrugTargetsIndication121923_text_201222
DrugTargetsIndication121923_text_201261
DrugTargetsIndication121923_text_200761
DrugTargetsIndication121923_text_200776
DrugTargetsIndication121923_text_200786
DrugTargetsIndication121923_text_200797
DrugTargetsIndication121923_text_200887
DrugTargetsIndication121923_text_201002
DrugTargetsIndication121923_text_201016
DrugTargetsIndication121923_text_201046
DrugTargetsIndication121923_text_201087
DrugTargetsIndication121923_text_200731
DrugTargetsIndication121923_text_200737
DrugTargetsIndication121923_text_200917
DrugTargetsIndication121923_text_200997
DrugTargetsIndication121923_text_201107
DrugTargetsIndication121923_text_201112
DrugTargetsIndication121923_text_201221
DrugTargetsIndication121923_text_200716
DrugTargetsIndication121923_text_200732
DrugTargetsIndication121923_text_200741
DrugTargetsIndication121923_text_200752
DrugTargetsIndication121923_text_200962
DrugTargetsIndication121923_text_201141
DrugTargetsIndication121923_text_201147
DrugTargetsIndication121923_text_201241
DrugTargetsIndication121923_text_201242
DrugTargetsIndication121923_text_200847
DrugTargetsIndication121923_text_200881
DrugTargetsIndication121923_text_201056
DrugTargetsIndication121923_text_201146
DrugTargetsIndication121923_text_200857
DrugTargetsIndication121923_text_201031
DrugTargetsIndication121923_text_201081
DrugTargetsIndication121923_text_200886
DrugTargetsIndication121923_text_200911
DrugTargetsIndication121923_text_201302
DrugTargetsIndication121923_text_200802
DrugTargetsIndication121923_text_200877
DrugTargetsIndication121923_text_201316
DrugTargetsIndication121923_text_201317
DrugTargetsIndication121923_text_200921
DrugTargetsIndication121923_text_201032
DrugTargetsIndication121923_text_201037
DrugTargetsIndication121923_text_201041
DrugTargetsIndication121923_text_201097
DrugTargetsIndication121923_text_200926
DrugTargetsIndication121923_text_200982
DrugTargetsIndication121923_text_201252
DrugTargetsIndication121923_text_201336
DrugTargetsIndication121923_text_200896
DrugTargetsIndication121923_text_201116
DrugTargetsIndication121923_text_201251
DrugTargetsIndication121923_text_201312
DrugTargetsIndication121923_text_200821
DrugTargetsIndication121923_text_200937
DrugTargetsIndication121923_text_201186
DrugTargetsIndication121923_text_201196
DrugTargetsIndication121923_text_201311
DrugTargetsIndication121923_text_201337
DrugTargetsIndication121923_text_200756
DrugTargetsIndication121923_text_200832
DrugTargetsIndication121923_text_200872
DrugTargetsIndication121923_text_201057
DrugTargetsIndication121923_text_201237
DrugTargetsIndication121923_text_201257
DrugTargetsIndication121923_text_201297
DrugTargetsIndication121923_text_200831
DrugTargetsIndication121923_text_200866
DrugTargetsIndication121923_text_201092
DrugTargetsIndication121923_text_201127
DrugTargetsIndication121923_text_201132
DrugTargetsIndication121923_text_201202
DrugTargetsIndication121923_text_201281
DrugTargetsIndication121923_text_201287
DrugTargetsIndication121923_text_200767
DrugTargetsIndication121923_text_200841
DrugTargetsIndication121923_text_200947
DrugTargetsIndication121923_text_201022
DrugTargetsIndication121923_text_201091
DrugTargetsIndication121923_text_201102
DrugTargetsIndication121923_text_201236
DrugTargetsIndication121923_text_200727
DrugTargetsIndication121923_text_200966
DrugTargetsIndication121923_text_200762
DrugTargetsIndication121923_text_201272
DrugTargetsIndication121923_text_201282",7/22/2024,Maya,,,,,,What are the approved uses for x?,x has been approved by the FDA to treat [comma sep list with and]. ,The drug x has not been approved by the FDA for treatment of any disease but has reached phase y clinical trials.
Q8,Is Rg-7841 approved by the FDA for any disease treatment?,The drug Rg-7841 is not approved by the FDA for treatment of any disease but has reached phase 1 clinical trials.,"DrugGeneTargets_text_44
DrugGeneTargets_text_115
DrugGeneTargets_text_185
DrugGeneTargets_text_255
DrugGeneTargets_text_326
DrugGeneTargets_text_396
DrugGeneTargets_text_467
DrugGeneTargets_text_538
DrugGeneTargets_text_609
DrugGeneTargets_text_679
DrugGeneTargets_text_749
DrugGeneTargets_text_819
DrugGeneTargets_text_890
DrugGeneTargets_text_961
DrugGeneTargets_text_1032
DrugGeneTargets_text_13479",7/22/2024,Maya ,,,,,,Is x approved by the FDA for any disease treatment?,,
Q9,Is Vinblastine Sulfate approved by the FDA and if so when was it?,"Yes, the drug Vinblastine Sulfate was first FDA approved for use in 1965.","DrugGeneTargets_text_48
DrugGeneTargets_text_119
DrugGeneTargets_text_189
DrugGeneTargets_text_259
DrugGeneTargets_text_330
DrugGeneTargets_text_400
DrugGeneTargets_text_471
DrugGeneTargets_text_542
DrugGeneTargets_text_613
DrugGeneTargets_text_683
DrugGeneTargets_text_753
DrugGeneTargets_text_823
DrugGeneTargets_text_894
DrugGeneTargets_text_965
DrugGeneTargets_text_1036",7/22/2024,Maya,,,,,,Is x approved by the FDA and if so when was it?,,
Q10,Are there any CR1 SNPs that have a statistically significant association with Alzheimer's Disease?,"Yes, the CR1 gene has four SNPs that are statistically significant in Alzheimer's Disease. Here are the SNPs along with their adjusted SMR p-values:

•rs679515:
  •Found in the prefrontal cortex, whole brain, multi ancestry whole brain, and cortex datasets
  •Multi SNP SMR p-values: 1.08e-12 (prefrontal cortex), 2.10e-12 (whole brain), 2.09e-15 (multi ancestry whole brain), and 4.46e-08 (cortex)
  •HEIDI values: 0.0028 (prefrontal cortex), 0.2568 (whole brain), 9.09e-08 (multi ancestry whole brain), and 0.9563 (cortex)
•rs1830763:
  •Found in the cortex and cerebellum
  •Multi SNP SMR p-values: 3.83e-15 (cortex), 1.72e-08 (cerebellum)
  •HEIDI values: 0.0603 (cortex), 0.1092 (cerebellum)
•rs2093760:
  •Found in the caudate basal ganglia dataset
  •Multi SNP SMR p-value: 3.25e-08
  •HEIDI value: 0.5329
•rs6697005:
  •Found in the basal ganglia dataset
  •Multi SNP SMR p-value: 2.48e-08
  •HEIDI value: 0.0786
","NDD_SMR_genes_all_update_text_2441
NDD_SMR_genes_all_update_text_1105231
NDD_SMR_genes_all_update_text_1265685
NDD_SMR_genes_all_update_text_24520
NDD_SMR_genes_all_update_text_1195476
NDD_SMR_genes_all_update_text_1605472
NDD_SMR_genes_all_update_text_1389608
NDD_SMR_genes_all_update_text_1244290",7/26/2024,Maya,,,,,,Are there any x SNPs that have a statistically significant association with y?,Yes there are (count significant) SNPs that's have a significant association with y. Here are the top 5:  snp tissue pvalue effect size ,"No, based on the (list tissue samples comma separated with second to last one separated by , and ) samples tested there are no alleles within the gene x that are significantly associated with Y."
Q11,Is ANGPTL8 significantly associated with any neurological diseases?,"No, based on the research conducted on the following neurological diseases, the gene ANGPTL8 is not found to be significantly associated with:
Alzheimer's Disease (AD)
Frontotemporal Dementia (FTD)
Lewy Body Dementia (LBD)
Parkinson's Disease (PD)
Amyotrophic Lateral Sclerosis (ALS)
Progressive Supranuclear Palsy (PSP)","NDD_SMR_genes_all_update_text_1107751
NDD_SMR_genes_all_update_text_1151716
NDD_SMR_genes_all_update_text_1114471
NDD_SMR_genes_all_update_text_1126904
NDD_SMR_genes_all_update_text_1139723
NDD_SMR_genes_all_update_text_1138430",7/22/2024,Maya/Marzieh,,,,,,Is x significantly associated with any neurological diseases?,,
Q12,what other names are there for the drug Vinblastine Sulfate?,"Some additional names for Vinblastine Sulfate are 29060-LE, 29060LE, Alkaban-aq, NSC-49842, Vinblastine sulphate, Vinblastini sulfas, and Vincaleukoblastine sulfateVlb monosulfate.","DrugGeneTargets_text_48
DrugGeneTargets_text_119
DrugGeneTargets_text_189
DrugGeneTargets_text_259
DrugGeneTargets_text_330
DrugGeneTargets_text_400
DrugGeneTargets_text_471
DrugGeneTargets_text_542
DrugGeneTargets_text_613
DrugGeneTargets_text_683
DrugGeneTargets_text_753
DrugGeneTargets_text_823
DrugGeneTargets_text_894
DrugGeneTargets_text_965
DrugGeneTargets_text_1036",7/22/2024,Maya,,,,,,what other names are there for the drug x?,,
Q13,When was Escitalopram approved by the FDA?,The drug Escitalopram was first FDA approved for use in 2002.,DrugGeneTargets_text_1476,7/22/2024,Maya,,,,,,,,
Q14,What mechanism type does the drug Testosterone Enanthate use? ,The drug Testosterone Enanthate is an agonist. ,DrugGeneTargets_text_5109,7/22/2024,Maya,,,,,,What mechanism type does the drug x use? ,,
Q15,Has Mifamurtide been removed from the market? ,"No , the drug Mifamurtide has not been withdrawn from the market. ","DrugGeneTargets_text_13688
DrugGeneTargets_text_13689",7/22/2024,Maya,,,,,,Has x been removed from the market? ,,
Q16,What gene does the drug Ocaliva target?,Ocaliva targets the gene NR1H4.,"DrugTargetsIndication121923_text_1104360
DrugTargetsIndication121923_text_1104361
DrugTargetsIndication121923_text_1104363
DrugTargetsIndication121923_text_1104405
DrugTargetsIndication121923_text_1104435
DrugTargetsIndication121923_text_1104479
DrugTargetsIndication121923_text_1104448
DrugTargetsIndication121923_text_1104344
DrugTargetsIndication121923_text_1104541
DrugTargetsIndication121923_text_1104555
DrugTargetsIndication121923_text_1104585
DrugTargetsIndication121923_text_1104394
DrugTargetsIndication121923_text_1104410
DrugTargetsIndication121923_text_1104517
DrugTargetsIndication121923_text_1104429
DrugTargetsIndication121923_text_1104594
DrugTargetsIndication121923_text_1104378
DrugTargetsIndication121923_text_1104557
DrugTargetsIndication121923_text_1104440
DrugTargetsIndication121923_text_1104560
DrugTargetsIndication121923_text_1104564
DrugTargetsIndication121923_text_1104439
DrugTargetsIndication121923_text_1104325
DrugTargetsIndication121923_text_1104355
DrugTargetsIndication121923_text_1104356
DrugTargetsIndication121923_text_1104315
DrugTargetsIndication121923_text_1104377
DrugTargetsIndication121923_text_1104434
DrugTargetsIndication121923_text_1104321
DrugTargetsIndication121923_text_1104381
DrugTargetsIndication121923_text_1104397
DrugTargetsIndication121923_text_1104591
DrugTargetsIndication121923_text_1104536
DrugTargetsIndication121923_text_1104580
DrugTargetsIndication121923_text_1104407
DrugTargetsIndication121923_text_1104574
DrugTargetsIndication121923_text_1104532
DrugTargetsIndication121923_text_1104313
DrugTargetsIndication121923_text_1104326
DrugTargetsIndication121923_text_1104330
DrugTargetsIndication121923_text_1104408
DrugTargetsIndication121923_text_1104572
DrugTargetsIndication121923_text_1104426
DrugTargetsIndication121923_text_1104340
DrugTargetsIndication121923_text_1104384
DrugTargetsIndication121923_text_1104433
DrugTargetsIndication121923_text_1104520
DrugTargetsIndication121923_text_1104566
DrugTargetsIndication121923_text_1104392
DrugTargetsIndication121923_text_1104452
DrugTargetsIndication121923_text_1104482
DrugTargetsIndication121923_text_1104527
DrugTargetsIndication121923_text_1104337
DrugTargetsIndication121923_text_1104508
DrugTargetsIndication121923_text_1104317
DrugTargetsIndication121923_text_1104543
DrugTargetsIndication121923_text_1104500
DrugTargetsIndication121923_text_1104515
DrugTargetsIndication121923_text_1104338
DrugTargetsIndication121923_text_1104341
DrugTargetsIndication121923_text_1104371
DrugTargetsIndication121923_text_1104418
DrugTargetsIndication121923_text_1104446
DrugTargetsIndication121923_text_1104463
DrugTargetsIndication121923_text_1104476
DrugTargetsIndication121923_text_1104595
DrugTargetsIndication121923_text_1104464
DrugTargetsIndication121923_text_1104480
DrugTargetsIndication121923_text_1104509
DrugTargetsIndication121923_text_1104554
DrugTargetsIndication121923_text_1104556
DrugTargetsIndication121923_text_1104573
DrugTargetsIndication121923_text_1104478
DrugTargetsIndication121923_text_1104455
DrugTargetsIndication121923_text_1104348
DrugTargetsIndication121923_text_1104569
DrugTargetsIndication121923_text_1104470
DrugTargetsIndication121923_text_1104349
DrugTargetsIndication121923_text_1104469
DrugTargetsIndication121923_text_1104605
DrugTargetsIndication121923_text_1104501
DrugTargetsIndication121923_text_1104431
DrugTargetsIndication121923_text_1104347
DrugTargetsIndication121923_text_1104428
DrugTargetsIndication121923_text_1104495
DrugTargetsIndication121923_text_1104586
DrugTargetsIndication121923_text_1104587
DrugTargetsIndication121923_text_1104559
DrugTargetsIndication121923_text_1104518
DrugTargetsIndication121923_text_1104606
DrugTargetsIndication121923_text_1104504
DrugTargetsIndication121923_text_1104318
DrugTargetsIndication121923_text_1104601
DrugTargetsIndication121923_text_1104380
DrugTargetsIndication121923_text_1104395
DrugTargetsIndication121923_text_1104367
DrugTargetsIndication121923_text_1104458
DrugTargetsIndication121923_text_1104563
DrugTargetsIndication121923_text_1104608
DrugTargetsIndication121923_text_1104460
DrugTargetsIndication121923_text_1104490
DrugTargetsIndication121923_text_1104492
DrugTargetsIndication121923_text_1104537
DrugTargetsIndication121923_text_1104583
DrugTargetsIndication121923_text_1104333
DrugTargetsIndication121923_text_1104387
DrugTargetsIndication121923_text_1104491
DrugTargetsIndication121923_text_1104353
DrugTargetsIndication121923_text_1104427
DrugTargetsIndication121923_text_1104443
DrugTargetsIndication121923_text_1104531
DrugTargetsIndication121923_text_1104400
DrugTargetsIndication121923_text_1104414
DrugTargetsIndication121923_text_1104521
DrugTargetsIndication121923_text_1104436
DrugTargetsIndication121923_text_1104600
DrugTargetsIndication121923_text_1104379
DrugTargetsIndication121923_text_1104412
DrugTargetsIndication121923_text_1104309
DrugTargetsIndication121923_text_1104415
DrugTargetsIndication121923_text_1104582
DrugTargetsIndication121923_text_1104596
DrugTargetsIndication121923_text_1104421
DrugTargetsIndication121923_text_1104422
DrugTargetsIndication121923_text_1104467
DrugTargetsIndication121923_text_1104364
DrugTargetsIndication121923_text_1104365
DrugTargetsIndication121923_text_1104546
DrugTargetsIndication121923_text_1104417
DrugTargetsIndication121923_text_1104420
DrugTargetsIndication121923_text_1104451
DrugTargetsIndication121923_text_1104603
DrugTargetsIndication121923_text_1104590
DrugTargetsIndication121923_text_1104402
DrugTargetsIndication121923_text_1104523
DrugTargetsIndication121923_text_1104534
DrugTargetsIndication121923_text_1104393
DrugTargetsIndication121923_text_1104602
DrugTargetsIndication121923_text_1104471
DrugTargetsIndication121923_text_1104472
DrugTargetsIndication121923_text_1104339
DrugTargetsIndication121923_text_1104538
DrugTargetsIndication121923_text_1104375
DrugTargetsIndication121923_text_1104419
DrugTargetsIndication121923_text_1104483
DrugTargetsIndication121923_text_1104514
DrugTargetsIndication121923_text_1104403
DrugTargetsIndication121923_text_1104581
DrugTargetsIndication121923_text_1104525
DrugTargetsIndication121923_text_1104540
DrugTargetsIndication121923_text_1104350
DrugTargetsIndication121923_text_1104484
DrugTargetsIndication121923_text_1104593
DrugTargetsIndication121923_text_1104386
DrugTargetsIndication121923_text_1104558
DrugTargetsIndication121923_text_1104545
DrugTargetsIndication121923_text_1104366
DrugTargetsIndication121923_text_1104370
DrugTargetsIndication121923_text_1104416
DrugTargetsIndication121923_text_1104376
DrugTargetsIndication121923_text_1104512
DrugTargetsIndication121923_text_1104505
DrugTargetsIndication121923_text_1104332
DrugTargetsIndication121923_text_1104390
DrugTargetsIndication121923_text_1104494
DrugTargetsIndication121923_text_1104528
DrugTargetsIndication121923_text_1104409
DrugTargetsIndication121923_text_1104589
DrugTargetsIndication121923_text_1104503
DrugTargetsIndication121923_text_1104553
DrugTargetsIndication121923_text_1104404
DrugTargetsIndication121923_text_1104544
DrugTargetsIndication121923_text_1104383
DrugTargetsIndication121923_text_1104398
DrugTargetsIndication121923_text_1104310
DrugTargetsIndication121923_text_1104565
DrugTargetsIndication121923_text_1104496
DrugTargetsIndication121923_text_1104529
DrugTargetsIndication121923_text_1104575
DrugTargetsIndication121923_text_1104352
DrugTargetsIndication121923_text_1104328
DrugTargetsIndication121923_text_1104598
DrugTargetsIndication121923_text_1104497
DrugTargetsIndication121923_text_1104457
DrugTargetsIndication121923_text_1104312
DrugTargetsIndication121923_text_1104342
DrugTargetsIndication121923_text_1104447
DrugTargetsIndication121923_text_1104552
DrugTargetsIndication121923_text_1104499
DrugTargetsIndication121923_text_1104411
DrugTargetsIndication121923_text_1104488
DrugTargetsIndication121923_text_1104533
DrugTargetsIndication121923_text_1104327
DrugTargetsIndication121923_text_1104391
DrugTargetsIndication121923_text_1104588
DrugTargetsIndication121923_text_1104319
DrugTargetsIndication121923_text_1104437
DrugTargetsIndication121923_text_1104466
DrugTargetsIndication121923_text_1104468
DrugTargetsIndication121923_text_1104516
DrugTargetsIndication121923_text_1104444
DrugTargetsIndication121923_text_1104519
DrugTargetsIndication121923_text_1104549
DrugTargetsIndication121923_text_1104567
DrugTargetsIndication121923_text_1104438
DrugTargetsIndication121923_text_1104524
DrugTargetsIndication121923_text_1104542
DrugTargetsIndication121923_text_1104604
DrugTargetsIndication121923_text_1104413
DrugTargetsIndication121923_text_1104578
DrugTargetsIndication121923_text_1104462
DrugTargetsIndication121923_text_1104477
DrugTargetsIndication121923_text_1104486
DrugTargetsIndication121923_text_1104487
DrugTargetsIndication121923_text_1104358
DrugTargetsIndication121923_text_1104331
DrugTargetsIndication121923_text_1104334
DrugTargetsIndication121923_text_1104473
DrugTargetsIndication121923_text_1104576
DrugTargetsIndication121923_text_1104577
DrugTargetsIndication121923_text_1104314
DrugTargetsIndication121923_text_1104423
DrugTargetsIndication121923_text_1104485
DrugTargetsIndication121923_text_1104547
DrugTargetsIndication121923_text_1104357
DrugTargetsIndication121923_text_1104399
DrugTargetsIndication121923_text_1104430
DrugTargetsIndication121923_text_1104535
DrugTargetsIndication121923_text_1104346
DrugTargetsIndication121923_text_1104362
DrugTargetsIndication121923_text_1104511
DrugTargetsIndication121923_text_1104530
DrugTargetsIndication121923_text_1104502
DrugTargetsIndication121923_text_1104324
DrugTargetsIndication121923_text_1104354
DrugTargetsIndication121923_text_1104401
DrugTargetsIndication121923_text_1104506
DrugTargetsIndication121923_text_1104374
DrugTargetsIndication121923_text_1104320
DrugTargetsIndication121923_text_1104335
DrugTargetsIndication121923_text_1104385
DrugTargetsIndication121923_text_1104474
DrugTargetsIndication121923_text_1104389
DrugTargetsIndication121923_text_1104465
DrugTargetsIndication121923_text_1104510
DrugTargetsIndication121923_text_1104454
DrugTargetsIndication121923_text_1104322
DrugTargetsIndication121923_text_1104432
DrugTargetsIndication121923_text_1104461
DrugTargetsIndication121923_text_1104568
DrugTargetsIndication121923_text_1104584
DrugTargetsIndication121923_text_1104562
DrugTargetsIndication121923_text_1104369
DrugTargetsIndication121923_text_1104522
DrugTargetsIndication121923_text_1104345
DrugTargetsIndication121923_text_1104359
DrugTargetsIndication121923_text_1104450
DrugTargetsIndication121923_text_1104526
DrugTargetsIndication121923_text_1104539
DrugTargetsIndication121923_text_1104599
DrugTargetsIndication121923_text_1104424
DrugTargetsIndication121923_text_1104368
DrugTargetsIndication121923_text_1104382
DrugTargetsIndication121923_text_1104372
DrugTargetsIndication121923_text_1104388
DrugTargetsIndication121923_text_1104475
DrugTargetsIndication121923_text_1104551
DrugTargetsIndication121923_text_1104513
DrugTargetsIndication121923_text_1104425
DrugTargetsIndication121923_text_1104351
DrugTargetsIndication121923_text_1104441
DrugTargetsIndication121923_text_1104548
DrugTargetsIndication121923_text_1104343
DrugTargetsIndication121923_text_1104445
DrugTargetsIndication121923_text_1104597
DrugTargetsIndication121923_text_1104316
DrugTargetsIndication121923_text_1104329
DrugTargetsIndication121923_text_1104481
DrugTargetsIndication121923_text_1104442
DrugTargetsIndication121923_text_1104550
DrugTargetsIndication121923_text_1104498
DrugTargetsIndication121923_text_1104396
DrugTargetsIndication121923_text_1104592
DrugTargetsIndication121923_text_1104607
DrugTargetsIndication121923_text_1104373
DrugTargetsIndication121923_text_1104489
DrugTargetsIndication121923_text_1104579
DrugTargetsIndication121923_text_1104406
DrugTargetsIndication121923_text_1104453
DrugTargetsIndication121923_text_1104571
DrugTargetsIndication121923_text_1104561
DrugTargetsIndication121923_text_1104449
DrugTargetsIndication121923_text_1104336
DrugTargetsIndication121923_text_1104311
DrugTargetsIndication121923_text_1104570
DrugTargetsIndication121923_text_1104323
DrugTargetsIndication121923_text_1104456
DrugTargetsIndication121923_text_1104459
DrugTargetsIndication121923_text_1104493
DrugTargetsIndication121923_text_1104507",7/22/2024,Maya/Mary,,,,,,What gene does the drug x target?,,
Q17,For which condition is Sonidegib Phosphate indicated according to the Experimental Factor Ontology (EFO) and Medical Subject Headings (MeSH)?,"Sonidegib Phosphate is indicated for the treatment of basal cell carcinoma, according to EFO (EFO:0004193) and MeSH (Carcinoma, Basal Cell, D002280).","DrugTargetsIndication121923_text_1072620 
DrugTargetsIndication121923_text_1072622 
DrugTargetsIndication121923_text_1072621",July 3th,Marzieh,,,,,,,,
Q18,What SNP is most significantly associated with AD in Caudate Basal Ganglia?,"The most significantly associated SNP with Alzheimer's Disease in the Caudate Basal Ganglia is rs2288911, located in the APOC2 gene, with a multi SMR p value of 1.951e-10
and a p HEIDI value of 2.226e-07.",NDD_SMR_genes_all_update_text_1268425,07/17/2024,Maya,,,,,,What SNP is most significantly associated with AD in x?,,
Q19,How do the associations between rs10256524 and Alzheimer's disease or Parkinson's disease risk differ across different brain tissues?,"The associations between rs10256524 and Alzheimer's disease or Parkinson's disease risk differ across the Amygdala and the Frontal Cortex BA9. 
Parkinson's Disease:
• In the Amygdala, rs10256524 exhibits a functionally significant association (P-SMR multi = 2.339e-06, p-HEIDI = 0.018).
• Similarly, in the Frontal Cortex BA9, rs10256524 shows a functionally significant association (P-SMR multi = 4.735e-07, p-HEIDI = 0.013).
Alzheimer's Disease:
• In the Amygdala, rs10256524 does not show a functionally significant association (P-SMR multi = 0.252, p-HEIDI = 0.538).
• Likewise, in the Frontal Cortex BA9, rs10256524 does not exhibit a functionally significant association (P-SMR multi = 0.278, p-HEIDI = 0.527).","NDD_SMR_genes_all_update_text_1167541
NDD_SMR_genes_all_update_text_1155910
NDD_SMR_genes_all_update_text_1603159
NDD_SMR_genes_all_update_text_1597657
",07/22/2024,Maya,,,,,,,,
Q20,"How many synonym names does Sonidegib Phosphate have, and what are they?","Sonidegib Phosphate has 3 synonym names: Erismodegib phosphate, Sonidegib diphosphate, and Sonidegib phosphate.","DrugTargetsIndication121923_text_1072620 
DrugTargetsIndication121923_text_1072622 
DrugTargetsIndication121923_text_1072621",July 3th,Marzieh,,,,,,,,
Q21,What is Aplenzin?,"Aplenzin, also known generically as bupropion hydrobromide, is used to treat major depressive disorder. It is a single protein drug that acts as an inhibitor. ","DrugTargetsIndication121923_text_434167
DrugTargetsIndication121923_text_434188
DrugTargetsIndication121923_text_434177
DrugTargetsIndication121923_text_434149
DrugTargetsIndication121923_text_434153
DrugTargetsIndication121923_text_434189
DrugTargetsIndication121923_text_434224
DrugTargetsIndication121923_text_434229
DrugTargetsIndication121923_text_434203
DrugTargetsIndication121923_text_434168
DrugTargetsIndication121923_text_434205
DrugTargetsIndication121923_text_434183
DrugTargetsIndication121923_text_434238
DrugTargetsIndication121923_text_434200
DrugTargetsIndication121923_text_434162
DrugTargetsIndication121923_text_434191
DrugTargetsIndication121923_text_434212
DrugTargetsIndication121923_text_434223
DrugTargetsIndication121923_text_434222
DrugTargetsIndication121923_text_434166
DrugTargetsIndication121923_text_434192
DrugTargetsIndication121923_text_434213
DrugTargetsIndication121923_text_434146
DrugTargetsIndication121923_text_434232
DrugTargetsIndication121923_text_434171
DrugTargetsIndication121923_text_434227
DrugTargetsIndication121923_text_434173
DrugTargetsIndication121923_text_434176
DrugTargetsIndication121923_text_434204
DrugTargetsIndication121923_text_434147
DrugTargetsIndication121923_text_434230
DrugTargetsIndication121923_text_434161
DrugTargetsIndication121923_text_434198
DrugTargetsIndication121923_text_434226
DrugTargetsIndication121923_text_434233
DrugTargetsIndication121923_text_434156
DrugTargetsIndication121923_text_434196
DrugTargetsIndication121923_text_434197
DrugTargetsIndication121923_text_434195
DrugTargetsIndication121923_text_434219
DrugTargetsIndication121923_text_434178
DrugTargetsIndication121923_text_434182
DrugTargetsIndication121923_text_434193
DrugTargetsIndication121923_text_434235
DrugTargetsIndication121923_text_434155
DrugTargetsIndication121923_text_434165
DrugTargetsIndication121923_text_434151
DrugTargetsIndication121923_text_434152
DrugTargetsIndication121923_text_434225
DrugTargetsIndication121923_text_434159
DrugTargetsIndication121923_text_434187
DrugTargetsIndication121923_text_434234
DrugTargetsIndication121923_text_434239
DrugTargetsIndication121923_text_434172
DrugTargetsIndication121923_text_434174
DrugTargetsIndication121923_text_434181
DrugTargetsIndication121923_text_434208
DrugTargetsIndication121923_text_434214
DrugTargetsIndication121923_text_434216
DrugTargetsIndication121923_text_434194
DrugTargetsIndication121923_text_434228
DrugTargetsIndication121923_text_434199
DrugTargetsIndication121923_text_434221
DrugTargetsIndication121923_text_434157
DrugTargetsIndication121923_text_434215
DrugTargetsIndication121923_text_434218
DrugTargetsIndication121923_text_434164
DrugTargetsIndication121923_text_434180
DrugTargetsIndication121923_text_434184
DrugTargetsIndication121923_text_434145
DrugTargetsIndication121923_text_434158
DrugTargetsIndication121923_text_434160
DrugTargetsIndication121923_text_434150
DrugTargetsIndication121923_text_434185
DrugTargetsIndication121923_text_434163
DrugTargetsIndication121923_text_434210
DrugTargetsIndication121923_text_434220
DrugTargetsIndication121923_text_434236
DrugTargetsIndication121923_text_434148
DrugTargetsIndication121923_text_434169
DrugTargetsIndication121923_text_434217
DrugTargetsIndication121923_text_434237
DrugTargetsIndication121923_text_434201
DrugTargetsIndication121923_text_434170
DrugTargetsIndication121923_text_434202
DrugTargetsIndication121923_text_434144
DrugTargetsIndication121923_text_434175
DrugTargetsIndication121923_text_434231
DrugTargetsIndication121923_text_434179
DrugTargetsIndication121923_text_434206
DrugTargetsIndication121923_text_434207
DrugTargetsIndication121923_text_434211
DrugTargetsIndication121923_text_434190
DrugTargetsIndication121923_text_434186
DrugTargetsIndication121923_text_434209
DrugTargetsIndication121923_text_434154",07/22/2024,Mary/Maya,,,,,,,,
Q22,Have any drugs targeting proteins been withdrawn from the market?,"Yes, there are drugs targeting proteins that have been withdrawn from the market. Two examples are Calcitonin and Peginesatide Acetate.","DrugGeneTargets_text_11099, DrugGeneTargets_text_12182",05/07/2024,Mary,,,,,,Have any drugs targeting x been withdrawn from the market?,,
Q23,Are there any oligonucleotide therapies that are in phase 2 clinical trials?,"Yes, there are 16 oligonucleotide therapies that have a maximum clinical trial phase of 2:
Imetelstat Sodium, Vupanorsen, Bamosiran, Olpasiran, Suvodirsen, Sepofarsen, Aganirsen, Cenersen Sodium, Volanesorsen Sodium, Sapablursen, Prexigebersen, Cenersen, Cofirasersen, Gataparsen, Apatorsen, Danvatirsen. However, the data does not specify if these drugs did not pass phase 2 or are currently in it. ","DrugGeneTargets_text_13562
DrugGeneTargets_text_12630
DrugGeneTargets_text_5679
DrugGeneTargets_text_13332
DrugGeneTargets_text_12019
DrugGeneTargets_text_13605
DrugGeneTargets_text_12738
DrugGeneTargets_text_12048
DrugGeneTargets_text_13095
DrugGeneTargets_text_13156
DrugGeneTargets_text_13759
DrugGeneTargets_text_12056
DrugGeneTargets_text_12627
DrugGeneTargets_text_12828
DrugGeneTargets_text_12833
DrugGeneTargets_text_12838
DrugGeneTargets_text_13578
DrugGeneTargets_text_13388
DrugGeneTargets_text_12820",07/22/2024,Mary/Maya,,,,,,,,
Q24,What is the effect size of rs112485576 in Parkinson's disease?,"The effect size, or beta, of rs112485576 is -0.1871 according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).",PDno23andme_full_gene_notext_1635378,07/22/2024,Mary/Maya,,,,,,What is the effect size of x in Parkinson's disease?,,
Q25,How many SNPs are genome-wide significant in chr10 for Parkinson's disease?,"There are 4 SNPs that are genome-wide significant (p<5E-8) within chr10 in the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).
The p-values are as follows:

- rs118117788 (p=1.328e-09)
- rs144814361 (p=9.065e-11)
- rs117896735 (p=2.829e-10)
- rs188789342 (p=8.491e-10)","PDno23andme_full_gene_notext_1145950
PDno23andme_full_gene_notext_4158122
PDno23andme_full_gene_notext_933245
PDno23andme_full_gene_notext_4171570",07/22/2024,Mary/Marzieh,,,,,,,,
Q26,When was Donepezil approved to treat Alzheimer's disease?,The drug Donepezil was approved to treat Alzheimer's disease in 1996. ,"DrugTargetsIndication121923_text_993824
DrugTargetsIndication121923_text_993944
DrugTargetsIndication121923_text_993884
DrugTargetsIndication121923_text_993800
DrugTargetsIndication121923_text_993896
DrugTargetsIndication121923_text_993788
DrugTargetsIndication121923_text_993920
DrugTargetsIndication121923_text_993836
DrugTargetsIndication121923_text_993860
DrugTargetsIndication121923_text_993908
DrugTargetsIndication121923_text_993848
DrugTargetsIndication121923_text_993812
DrugTargetsIndication121923_text_993872
DrugTargetsIndication121923_text_993956
DrugTargetsIndication121923_text_993932",7/22/2024,Maya,,,,,,,,
Q27,What drugs are approved to treat AD? ,"There are two drugs that are approved to treat Alzheimer's disease:
• Donepezil Hydrochloride, which was approved in 1996
•Memantine Hydrochloride, which was approved in 2003
","DrugTargetsIndication121923_text_993836
DrugTargetsIndication121923_text_455022
DrugTargetsIndication121923_text_455428
DrugTargetsIndication121923_text_454994
DrugTargetsIndication121923_text_455554
DrugTargetsIndication121923_text_455708
DrugTargetsIndication121923_text_993824
DrugTargetsIndication121923_text_993944
DrugTargetsIndication121923_text_455246
DrugTargetsIndication121923_text_455568
DrugTargetsIndication121923_text_455288
DrugTargetsIndication121923_text_455316
DrugTargetsIndication121923_text_455064
DrugTargetsIndication121923_text_455106
DrugTargetsIndication121923_text_993848
DrugTargetsIndication121923_text_993884
DrugTargetsIndication121923_text_455190
DrugTargetsIndication121923_text_455386
DrugTargetsIndication121923_text_455218
DrugTargetsIndication121923_text_455302
DrugTargetsIndication121923_text_455652
DrugTargetsIndication121923_text_455274
DrugTargetsIndication121923_text_455512
DrugTargetsIndication121923_text_455596
DrugTargetsIndication121923_text_455134
DrugTargetsIndication121923_text_455414
DrugTargetsIndication121923_text_455120
DrugTargetsIndication121923_text_455722
DrugTargetsIndication121923_text_455638
DrugTargetsIndication121923_text_455260
DrugTargetsIndication121923_text_455400
DrugTargetsIndication121923_text_455092
DrugTargetsIndication121923_text_455456
DrugTargetsIndication121923_text_993860
DrugTargetsIndication121923_text_455050
DrugTargetsIndication121923_text_455750
DrugTargetsIndication121923_text_455484
DrugTargetsIndication121923_text_455736
DrugTargetsIndication121923_text_993920
DrugTargetsIndication121923_text_455344
DrugTargetsIndication121923_text_455610
DrugTargetsIndication121923_text_455442
DrugTargetsIndication121923_text_993956
DrugTargetsIndication121923_text_455204
DrugTargetsIndication121923_text_455498
DrugTargetsIndication121923_text_993908
DrugTargetsIndication121923_text_455162
DrugTargetsIndication121923_text_455470
DrugTargetsIndication121923_text_455540
DrugTargetsIndication121923_text_455148
DrugTargetsIndication121923_text_455372
DrugTargetsIndication121923_text_455036
DrugTargetsIndication121923_text_993788
DrugTargetsIndication121923_text_455680
DrugTargetsIndication121923_text_455330
DrugTargetsIndication121923_text_993800
DrugTargetsIndication121923_text_993896
DrugTargetsIndication121923_text_455666
DrugTargetsIndication121923_text_455078
DrugTargetsIndication121923_text_455694
DrugTargetsIndication121923_text_993872
DrugTargetsIndication121923_text_455176
DrugTargetsIndication121923_text_993812
DrugTargetsIndication121923_text_455232
DrugTargetsIndication121923_text_455358
DrugTargetsIndication121923_text_993932
DrugTargetsIndication121923_text_455008
DrugTargetsIndication121923_text_455526
DrugTargetsIndication121923_text_455582
DrugTargetsIndication121923_text_455624
DrugTargetsIndication121923_text_455764",7/22/2024,Maya,,,,,More but only listed two in table,,,
Q28,What SNP is most significantly associated with PSP in spinalcord tissue?,"The most significantly associated SNP with Progressive supranuclear palsy in Spinalcord eQTL omic data is rs8070723, located in the LRRC37A2 gene, with a multi SNP SMR p value of 2.163e-11 and a HEIDI value of 1.775e-07.",NDD_SMR_genes_all_update_text_30484,7/22/2024,Maya,,,,,,,,
Q29,Is the gene GRIA4 targeted by multiple different drugs to treat PD?,"Yes, the gene GRIA4 is targeted by two drugs for the treatment of PD:
•Topiramate
•Perampanel","DrugGeneTargets_text_8342
DrugGeneTargets_text_8345",7/22/2024,Maya,,,,,,,,
Q30,Has the FDA approved any drugs targeting the gene APOE for the treatment of neurodegenerative diseases?,No the FDA hasn't approved any drugs targeting the gene APOE for the treatment of neurodegenerative diseases.,`card-ai-389220.card_ai_june_mvp.DrugTargetIndications`,7/22/2024,Maya,,,,,,,,
Q31,What is the top SNP in blood for Lewy Body Dementia?,"The top SNP when analyzing whole blood in Lewy Body Dementia is rs17561351, located in the PVRL2 gene, with a multi SNP SMR p value of 2.638e-25 and a p Heidi of 2.172e-14",NDD_SMR_genes_all_update_text_1550598,7/22/2024,Mary/Maya,,,,,,What is the top SNP in x for y?,,
Q32,What is the allele frequency of the SNP rs2075650 in the context of Parkinson's disease?,"In GWAS summary statistics for PD from Nalls (2019), single nucleotide polymorphism rs2075650 has an alternate allele (G) frequency of 0.131 and reference
allele (A) frequency of 0.869.",PDno23andme_full_gene_notext_378423,7/22/2024,Maya,,,,,,,,
Q33,Which genes are targeted by the drug Levodopa in the treatment of Parkinson's disease?,"In the context of Parkinson's disease, the drug Levodopa targets the gene DRD3.","DrugTargetsIndication121923_text_205011
DrugTargetsIndication121923_text_205086
DrugTargetsIndication121923_text_204911
DrugTargetsIndication121923_text_204961
DrugTargetsIndication121923_text_204861
DrugTargetsIndication121923_text_205061
DrugTargetsIndication121923_text_205036
DrugTargetsIndication121923_text_204886
DrugTargetsIndication121923_text_204936
DrugTargetsIndication121923_text_204986",7/22/2024,Maya,,,,,,,,
Q34,Is the SNP rs12032182 significant in AD? ,"No, according to the GWAS summary statistics for AD from Bellenguez (2022), the SNP rs12032182 is not significant in AD. ",AD_combo_gene_notext_UUID_32322,7/22/2024,Maya,,,,,,,,
Q35,What is the genomic location of SNP rs12032182 ,"The SNP rs12032182 is located on chromosome 1:
• Genomic Build GrCh37/HG19: base pair position 4431315
• Genomic Build GrCh38: base pair position 4371255","AD_combo_gene_notext_UUID_32322
PDno23andme_full_gene_notext_6154340",7/22/2024,Maya,,,,,,What is the genomic location of SNP x?,"The SNP x is located on chromosome y:
• Genomic Build GrCh37/HG19: base pair position z
• Genomic Build GrCh38: base pair position q",The SNP rs1804519 is not listed in the data so I cannot identify its genomic location.
Q36,Which genes are targeted by the drug Dasatinib in the treatment of Alzheimer's disease?,"The drug Dasatinib has not been approved by the FDA as a treatment for Alzheimer's disease (AD), but it is currently undergoing evaluation in clinical trials for this purpose. However, there are 15 proposed gene targets: KIT, BCR, ABL1, PDGFRB, SRC, FRK, YES1, BLK, SRMS, LCK, LYN, FYN, EPHA2, FGR, and HCK.","DrugTargetsIndication121923_text_731956
DrugTargetsIndication121923_text_741628
DrugTargetsIndication121923_text_742408
DrugTargetsIndication121923_text_725638
DrugTargetsIndication121923_text_733594
DrugTargetsIndication121923_text_735388
DrugTargetsIndication121923_text_742720
DrugTargetsIndication121923_text_717760
DrugTargetsIndication121923_text_738040
DrugTargetsIndication121923_text_736714
DrugTargetsIndication121923_text_742486
DrugTargetsIndication121923_text_713704
DrugTargetsIndication121923_text_725170
DrugTargetsIndication121923_text_731020
DrugTargetsIndication121923_text_731254
DrugTargetsIndication121923_text_730162
DrugTargetsIndication121923_text_739288
DrugTargetsIndication121923_text_737338
DrugTargetsIndication121923_text_720880
DrugTargetsIndication121923_text_732112
DrugTargetsIndication121923_text_723688
DrugTargetsIndication121923_text_742018
DrugTargetsIndication121923_text_723610
DrugTargetsIndication121923_text_730552
DrugTargetsIndication121923_text_714406
DrugTargetsIndication121923_text_726340
DrugTargetsIndication121923_text_717604
DrugTargetsIndication121923_text_723922
DrugTargetsIndication121923_text_727978
DrugTargetsIndication121923_text_730396
DrugTargetsIndication121923_text_721582
DrugTargetsIndication121923_text_726106
DrugTargetsIndication121923_text_722752
DrugTargetsIndication121923_text_725326
DrugTargetsIndication121923_text_735076
DrugTargetsIndication121923_text_737104
DrugTargetsIndication121923_text_714796
DrugTargetsIndication121923_text_717682
DrugTargetsIndication121923_text_733360
DrugTargetsIndication121923_text_719398
DrugTargetsIndication121923_text_729226
DrugTargetsIndication121923_text_732580
DrugTargetsIndication121923_text_717214
DrugTargetsIndication121923_text_739210
DrugTargetsIndication121923_text_725014
DrugTargetsIndication121923_text_722128
DrugTargetsIndication121923_text_731488
DrugTargetsIndication121923_text_713158
DrugTargetsIndication121923_text_731566
DrugTargetsIndication121923_text_737026
DrugTargetsIndication121923_text_741472
DrugTargetsIndication121923_text_723064
DrugTargetsIndication121923_text_735934
DrugTargetsIndication121923_text_722284
DrugTargetsIndication121923_text_725950
DrugTargetsIndication121923_text_728758
DrugTargetsIndication121923_text_731722
DrugTargetsIndication121923_text_732424
DrugTargetsIndication121923_text_734842
DrugTargetsIndication121923_text_716122
DrugTargetsIndication121923_text_724546
DrugTargetsIndication121923_text_714484
DrugTargetsIndication121923_text_715186
DrugTargetsIndication121923_text_724000
DrugTargetsIndication121923_text_715810
DrugTargetsIndication121923_text_732034
DrugTargetsIndication121923_text_721972
DrugTargetsIndication121923_text_729304
DrugTargetsIndication121923_text_715264
DrugTargetsIndication121923_text_722596
DrugTargetsIndication121923_text_727354
DrugTargetsIndication121923_text_727120
DrugTargetsIndication121923_text_731878
DrugTargetsIndication121923_text_742330
DrugTargetsIndication121923_text_730240
DrugTargetsIndication121923_text_742798
DrugTargetsIndication121923_text_722908
DrugTargetsIndication121923_text_725092
DrugTargetsIndication121923_text_723454
DrugTargetsIndication121923_text_715654
DrugTargetsIndication121923_text_728992
DrugTargetsIndication121923_text_729148
DrugTargetsIndication121923_text_735544
DrugTargetsIndication121923_text_740770
DrugTargetsIndication121923_text_716980
DrugTargetsIndication121923_text_734140
DrugTargetsIndication121923_text_738508
DrugTargetsIndication121923_text_715420
DrugTargetsIndication121923_text_715576
DrugTargetsIndication121923_text_715732
DrugTargetsIndication121923_text_726418
DrugTargetsIndication121923_text_730318
DrugTargetsIndication121923_text_716044
DrugTargetsIndication121923_text_725560
DrugTargetsIndication121923_text_739600
DrugTargetsIndication121923_text_721660
DrugTargetsIndication121923_text_734452
DrugTargetsIndication121923_text_724390
DrugTargetsIndication121923_text_734920
DrugTargetsIndication121923_text_727276
DrugTargetsIndication121923_text_729850
DrugTargetsIndication121923_text_713314
DrugTargetsIndication121923_text_721114
DrugTargetsIndication121923_text_732502
DrugTargetsIndication121923_text_713548
DrugTargetsIndication121923_text_713626
DrugTargetsIndication121923_text_725872
DrugTargetsIndication121923_text_726262
DrugTargetsIndication121923_text_739444
DrugTargetsIndication121923_text_738742
DrugTargetsIndication121923_text_723844
DrugTargetsIndication121923_text_732814
DrugTargetsIndication121923_text_725248
DrugTargetsIndication121923_text_728290
DrugTargetsIndication121923_text_714172
DrugTargetsIndication121923_text_724858
DrugTargetsIndication121923_text_737494
DrugTargetsIndication121923_text_716434
DrugTargetsIndication121923_text_734062
DrugTargetsIndication121923_text_734998
DrugTargetsIndication121923_text_742174
DrugTargetsIndication121923_text_739834
DrugTargetsIndication121923_text_717136
DrugTargetsIndication121923_text_728446
DrugTargetsIndication121923_text_734764
DrugTargetsIndication121923_text_739678
DrugTargetsIndication121923_text_716356
DrugTargetsIndication121923_text_728680
DrugTargetsIndication121923_text_714718
DrugTargetsIndication121923_text_720100
DrugTargetsIndication121923_text_726028
DrugTargetsIndication121923_text_742252
DrugTargetsIndication121923_text_718540
DrugTargetsIndication121923_text_730006
DrugTargetsIndication121923_text_738274
DrugTargetsIndication121923_text_733984
DrugTargetsIndication121923_text_725482
DrugTargetsIndication121923_text_736012
DrugTargetsIndication121923_text_724156
DrugTargetsIndication121923_text_732190
DrugTargetsIndication121923_text_721738
DrugTargetsIndication121923_text_727744
DrugTargetsIndication121923_text_718462
DrugTargetsIndication121923_text_717994
DrugTargetsIndication121923_text_741862
DrugTargetsIndication121923_text_720412
DrugTargetsIndication121923_text_739912
DrugTargetsIndication121923_text_718306
DrugTargetsIndication121923_text_727432
DrugTargetsIndication121923_text_733126
DrugTargetsIndication121923_text_717292
DrugTargetsIndication121923_text_721270
DrugTargetsIndication121923_text_729460
DrugTargetsIndication121923_text_716668
DrugTargetsIndication121923_text_735622
DrugTargetsIndication121923_text_742642
DrugTargetsIndication121923_text_732268
DrugTargetsIndication121923_text_741316
DrugTargetsIndication121923_text_719164
DrugTargetsIndication121923_text_733750
DrugTargetsIndication121923_text_736558
DrugTargetsIndication121923_text_728056
DrugTargetsIndication121923_text_713470
DrugTargetsIndication121923_text_726574
DrugTargetsIndication121923_text_729616
DrugTargetsIndication121923_text_742954
DrugTargetsIndication121923_text_733282
DrugTargetsIndication121923_text_721816
DrugTargetsIndication121923_text_728914
DrugTargetsIndication121923_text_733048
DrugTargetsIndication121923_text_714640
DrugTargetsIndication121923_text_719086
DrugTargetsIndication121923_text_723298
DrugTargetsIndication121923_text_740380
DrugTargetsIndication121923_text_726652
DrugTargetsIndication121923_text_737650
DrugTargetsIndication121923_text_731098
DrugTargetsIndication121923_text_717916
DrugTargetsIndication121923_text_736324
DrugTargetsIndication121923_text_719476
DrugTargetsIndication121923_text_739366
DrugTargetsIndication121923_text_737884
DrugTargetsIndication121923_text_736402
DrugTargetsIndication121923_text_722830
DrugTargetsIndication121923_text_732892
DrugTargetsIndication121923_text_737416
DrugTargetsIndication121923_text_738352
DrugTargetsIndication121923_text_728836
DrugTargetsIndication121923_text_739054
DrugTargetsIndication121923_text_737728
DrugTargetsIndication121923_text_717058
DrugTargetsIndication121923_text_716278
DrugTargetsIndication121923_text_716512
DrugTargetsIndication121923_text_735466
DrugTargetsIndication121923_text_736636
DrugTargetsIndication121923_text_731332
DrugTargetsIndication121923_text_730630
DrugTargetsIndication121923_text_733516
DrugTargetsIndication121923_text_722674
DrugTargetsIndication121923_text_716590
DrugTargetsIndication121923_text_730942
DrugTargetsIndication121923_text_716200
DrugTargetsIndication121923_text_722206
DrugTargetsIndication121923_text_720022
DrugTargetsIndication121923_text_726184
DrugTargetsIndication121923_text_741004
DrugTargetsIndication121923_text_741784
DrugTargetsIndication121923_text_718774
DrugTargetsIndication121923_text_721192
DrugTargetsIndication121923_text_722440
DrugTargetsIndication121923_text_738664
DrugTargetsIndication121923_text_713860
DrugTargetsIndication121923_text_719320
DrugTargetsIndication121923_text_730084
DrugTargetsIndication121923_text_736246
DrugTargetsIndication121923_text_729382
DrugTargetsIndication121923_text_724702
DrugTargetsIndication121923_text_738430
DrugTargetsIndication121923_text_740224
DrugTargetsIndication121923_text_716902
DrugTargetsIndication121923_text_723532
DrugTargetsIndication121923_text_738898
DrugTargetsIndication121923_text_727588
DrugTargetsIndication121923_text_728368
DrugTargetsIndication121923_text_713392
DrugTargetsIndication121923_text_718930
DrugTargetsIndication121923_text_719554
DrugTargetsIndication121923_text_731644
DrugTargetsIndication121923_text_738976
DrugTargetsIndication121923_text_740614
DrugTargetsIndication121923_text_718852
DrugTargetsIndication121923_text_740692
DrugTargetsIndication121923_text_720958
DrugTargetsIndication121923_text_722518
DrugTargetsIndication121923_text_734686
DrugTargetsIndication121923_text_735232
DrugTargetsIndication121923_text_738586
DrugTargetsIndication121923_text_713782
DrugTargetsIndication121923_text_725794
DrugTargetsIndication121923_text_723766
DrugTargetsIndication121923_text_732736
DrugTargetsIndication121923_text_740302
DrugTargetsIndication121923_text_713938
DrugTargetsIndication121923_text_733906
DrugTargetsIndication121923_text_740068
DrugTargetsIndication121923_text_733204
DrugTargetsIndication121923_text_737806
DrugTargetsIndication121923_text_743032
DrugTargetsIndication121923_text_728212
DrugTargetsIndication121923_text_734530
DrugTargetsIndication121923_text_739990
DrugTargetsIndication121923_text_741082
DrugTargetsIndication121923_text_741238
DrugTargetsIndication121923_text_716824
DrugTargetsIndication121923_text_715108
DrugTargetsIndication121923_text_719710
DrugTargetsIndication121923_text_724780
DrugTargetsIndication121923_text_728602
DrugTargetsIndication121923_text_726730
DrugTargetsIndication121923_text_727666
DrugTargetsIndication121923_text_737572
DrugTargetsIndication121923_text_732346
DrugTargetsIndication121923_text_742876
DrugTargetsIndication121923_text_727510
DrugTargetsIndication121923_text_742096
DrugTargetsIndication121923_text_735700
DrugTargetsIndication121923_text_724078
DrugTargetsIndication121923_text_740146
DrugTargetsIndication121923_text_729070
DrugTargetsIndication121923_text_739132
DrugTargetsIndication121923_text_741706
DrugTargetsIndication121923_text_730708
DrugTargetsIndication121923_text_733672
DrugTargetsIndication121923_text_736948
DrugTargetsIndication121923_text_739756
DrugTargetsIndication121923_text_736090
DrugTargetsIndication121923_text_736168
DrugTargetsIndication121923_text_722050
DrugTargetsIndication121923_text_724312
DrugTargetsIndication121923_text_741160
DrugTargetsIndication121923_text_741940
DrugTargetsIndication121923_text_714952
DrugTargetsIndication121923_text_717526
DrugTargetsIndication121923_text_719242
DrugTargetsIndication121923_text_720334
DrugTargetsIndication121923_text_727822
DrugTargetsIndication121923_text_726964
DrugTargetsIndication121923_text_727042
DrugTargetsIndication121923_text_736480
DrugTargetsIndication121923_text_720646
DrugTargetsIndication121923_text_733438
DrugTargetsIndication121923_text_717448
DrugTargetsIndication121923_text_726496
DrugTargetsIndication121923_text_725716
DrugTargetsIndication121923_text_723376
DrugTargetsIndication121923_text_718696
DrugTargetsIndication121923_text_723142
DrugTargetsIndication121923_text_714562
DrugTargetsIndication121923_text_738196
DrugTargetsIndication121923_text_721036
DrugTargetsIndication121923_text_741550
DrugTargetsIndication121923_text_715966
DrugTargetsIndication121923_text_720802
DrugTargetsIndication121923_text_713236
DrugTargetsIndication121923_text_717838
DrugTargetsIndication121923_text_724936
DrugTargetsIndication121923_text_734374
DrugTargetsIndication121923_text_735778
DrugTargetsIndication121923_text_735856
DrugTargetsIndication121923_text_737260
DrugTargetsIndication121923_text_714328
DrugTargetsIndication121923_text_726808
DrugTargetsIndication121923_text_734608
DrugTargetsIndication121923_text_722362
DrugTargetsIndication121923_text_740458
DrugTargetsIndication121923_text_719788
DrugTargetsIndication121923_text_714874
DrugTargetsIndication121923_text_719866
DrugTargetsIndication121923_text_734218
DrugTargetsIndication121923_text_720490
DrugTargetsIndication121923_text_729928
DrugTargetsIndication121923_text_715030
DrugTargetsIndication121923_text_724234
DrugTargetsIndication121923_text_731176
DrugTargetsIndication121923_text_741394
DrugTargetsIndication121923_text_728524
DrugTargetsIndication121923_text_722986
DrugTargetsIndication121923_text_717370
DrugTargetsIndication121923_text_730864
DrugTargetsIndication121923_text_726886
DrugTargetsIndication121923_text_732970
DrugTargetsIndication121923_text_714016
DrugTargetsIndication121923_text_714250
DrugTargetsIndication121923_text_719008
DrugTargetsIndication121923_text_728134
DrugTargetsIndication121923_text_730474
DrugTargetsIndication121923_text_731410
DrugTargetsIndication121923_text_736792
DrugTargetsIndication121923_text_716746
DrugTargetsIndication121923_text_740926
DrugTargetsIndication121923_text_723220
DrugTargetsIndication121923_text_736870
DrugTargetsIndication121923_text_724624
DrugTargetsIndication121923_text_738820
DrugTargetsIndication121923_text_732658
DrugTargetsIndication121923_text_733828
DrugTargetsIndication121923_text_715342
DrugTargetsIndication121923_text_730786
DrugTargetsIndication121923_text_720724
DrugTargetsIndication121923_text_721504
DrugTargetsIndication121923_text_718228
DrugTargetsIndication121923_text_740536
DrugTargetsIndication121923_text_740848
DrugTargetsIndication121923_text_720256
DrugTargetsIndication121923_text_734296
DrugTargetsIndication121923_text_721894
DrugTargetsIndication121923_text_724468
DrugTargetsIndication121923_text_729694
DrugTargetsIndication121923_text_738118
DrugTargetsIndication121923_text_721348
DrugTargetsIndication121923_text_729538
DrugTargetsIndication121923_text_737962
DrugTargetsIndication121923_text_719632
DrugTargetsIndication121923_text_715888
DrugTargetsIndication121923_text_735310
DrugTargetsIndication121923_text_721426
DrugTargetsIndication121923_text_719944
DrugTargetsIndication121923_text_720178
DrugTargetsIndication121923_text_720568
DrugTargetsIndication121923_text_727900
DrugTargetsIndication121923_text_729772
DrugTargetsIndication121923_text_718618
DrugTargetsIndication121923_text_737182
DrugTargetsIndication121923_text_731800
DrugTargetsIndication121923_text_718150
DrugTargetsIndication121923_text_714094
DrugTargetsIndication121923_text_718072
DrugTargetsIndication121923_text_725404
DrugTargetsIndication121923_text_742564
DrugTargetsIndication121923_text_715498
DrugTargetsIndication121923_text_718384
DrugTargetsIndication121923_text_727198
DrugTargetsIndication121923_text_735154
DrugTargetsIndication121923_text_739522",7/22/2024,Maya,,,,,,,,
Q37,Have any antibody therapies been withdrawn from the market?,"Yes, the following antibody therapies have been removed from the market:
- Daclizumab
- Efalizumab","DrugGeneTargets_text_11328
DrugGeneTargets_text_11336
DrugGeneTargets_text_12881
DrugGeneTargets_text_10133
DrugGeneTargets_text_10142",07/22/2024,Mary/Maya,,,,,,,,
Q38,Are there any specific alleles within the gene CHRM3 associated with increased susceptibility to developing Alzheimer's disease?,"No, based on the blood, liver, and 
brain samples tested there are no alleles within the gene CHRM3 that are significantly associated with an increased susceptibility to developing Alzheimer's disease.","NDD_SMR_genes_all_update_text_42309
NDD_SMR_genes_all_update_text_1464887
NDD_SMR_genes_all_update_text_656801",7/22/2024,Maya,,,,,"follow up with ad gwas once genes are listed
also listing source at end will provide context ",,,
Q39,Can you discuss the expression patterns of the SLC3A1 gene and its potential role in neuroprotection against Parkinson's disease?,"The expression patterns of the SLC3A1 gene within in the cerebellum, whole blood, and cortex, suggest that SLC3A1 does not play a significant protective or harmful role in Parkinson's Disease (PD). 
Brain_Cerebellum:
•Top associated SNP: rs4953085 
•Multi SNP SMR p value: 0.1266087
•HEIDI value: 0.205407 
•b SMR value (effect size): 0.109181
Cerebellum_metaBrain:
•Top associated SNP: rs12987415 
•Multi SNP SMR p value: 0.08749322
•HEIDI value: 0.6051775 
•b SMR value (effect size): 0.068271
blood_eQTLgen:
•Top associated SNP: rs73924248 
•Multi SNP SMR p value: 0.4388553
•HEIDI value: 0.3562025 
•b SMR value (effect size):  -0.56736
blood_mcrae:
•Top associated SNP: rs3738984 
•Multi SNP SMR p value: 0.4639278
•HEIDI value: 0.4481285 
• b SMR value (effect size): -0.0372716
Cortex_metaBrain:
•Top associated SNP: rs7562945 
•Multi SNP SMR p value: 0.04325003
•HEIDI value: 0.3627226 
• b SMR value (effect size): 0.147513

The data indicates that SLC3A1 does not play a significant role in neuroprotection against Parkinson's Disease across the studied tissues. Notably, in both blood samples, the effect size is negative but not significant, indicating no substantial impact on neuroprotection.","NDD_SMR_genes_all_update_text_1143995
NDD_SMR_genes_all_update_text_19808
NDD_SMR_genes_all_update_text_1706781
NDD_SMR_genes_all_update_text_1553899
NDD_SMR_genes_all_update_text_1017060",7/22/2024,Maya,,,,,,,,
Q40,What is the genomic location of SNP's rs3738435 and rs1804519 in the GRCh38/hg38 build of the human genome and what gene are they located on or near?,"The SNP rs3738435 is located on the gene CHRM3 at position 239907303 in the GRCh38/hg38 build of the human genome.
The SNP rs1804519 is not listed in the data so I cannot identify its genomic location. ","AD_combo_gene_notext_UUID_1611832
PDno23andme_full_gene_notext_3078323",7/22/2024,Maya,,,,,,What is the genomic location of SNP x in the GRCh38/hg38 build of the human genome and what gene is it located on or near?,"The SNP x is located on the gene y at position z in the GRCh38/hg38 build of the human genome.
",The SNP x is not listed in the data so I cannot identify its genomic location.
Q41,What SNPs are significantly associated with Parkinson disease?,"Here is a table of the top 10 SNPs that are significantly associated with Parkinsons Disease: 
SNP        p-value
rs356203        3.01E-41
rs356219        3.47E-41
rs356220        3.92E-41
rs356215        1.01E-36
rs356182        9.41E-34
rs356225        2.51E-32
rs356221        2.52E-32
rs356204        2.87E-32
rs189596        4.29E-32
rs356200        5.61E-32","PDno23andme_full_gene_notext_1492093
PDno23andme_full_gene_notext_4541022
PDno23andme_full_gene_notext_3029756
PDno23andme_full_gene_notext_6349215
PDno23andme_full_gene_notext_7539504
PDno23andme_full_gene_notext_153395
PDno23andme_full_gene_notext_4449871
PDno23andme_full_gene_notext_6805650
PDno23andme_full_gene_notext_7042578
PDno23andme_full_gene_notext_3240570",7/17/2024,Maya,,,,,,,,
Q42,Tell me about GWAS in Alzheimer's Disease.,"Genome-wide association studies (GWAS) identify risk alleles that are associated with a particular disease. Here are the top 10 most significant risk SNPs in Alzheimer's Disease according to GWAS summary statistics for AD from Bellenguez (2022):
SNP        p-value
rs117310449        3.26E-115
rs144261139        5.17E-111
rs139644294        1.53E-94
rs6733839        6.48E-90
rs537741299        8.59E-84
rs61679753        2.28E-83
rs1160983        4.99E-83
rs111784051        1.01E-82
rs7254892        7.74E-82
rs79701229        5.34E-81","AD_combo_gene_notext_UUID_19974366
AD_combo_gene_notext_UUID_19974311
AD_combo_gene_notext_UUID_19974435
AD_combo_gene_notext_UUID_2643372
AD_combo_gene_notext_UUID_19974502
AD_combo_gene_notext_UUID_19974414
AD_combo_gene_notext_UUID_19974389
AD_combo_gene_notext_UUID_19974428
AD_combo_gene_notext_UUID_19974343
AD_combo_gene_notext_UUID_19974306",7/17/2024,Maya,,,,,,,,
Q43,What SNPs have been linked to the progression of Multiple Sclerosis?,"While I do not have any information regarding SNPs and Multiple Sclerosis, I do have information on the various drugs that are associated with treating the disease.  Would you like me to share this information instead? ",`card-ai-389220.card_ai_june_mvp.DrugTargetIndications`,7/22/2024,Maya,,,,,,,,
Q44,Is there an association between PSMF1 and Parkinson's disease?,"No, there is no significant association between PSMF1 and PD. ","NDD_SMR_genes_all_update_text_1243289
NDD_SMR_genes_all_update_text_1169184
NDD_SMR_genes_all_update_text_1021830
NDD_SMR_genes_all_update_text_1330012
NDD_SMR_genes_all_update_text_1281757
NDD_SMR_genes_all_update_text_1262680
NDD_SMR_genes_all_update_text_1730448
NDD_SMR_genes_all_update_text_500040
NDD_SMR_genes_all_update_text_1641095
NDD_SMR_genes_all_update_text_500039
NDD_SMR_genes_all_update_text_20464
NDD_SMR_genes_all_update_text_1437073
NDD_SMR_genes_all_update_text_1371355
NDD_SMR_genes_all_update_text_1566684
NDD_SMR_genes_all_update_text_1144479
NDD_SMR_genes_all_update_text_1021829
NDD_SMR_genes_all_update_text_500041
NDD_SMR_genes_all_update_text_500036
NDD_SMR_genes_all_update_text_500037
NDD_SMR_genes_all_update_text_1021831
NDD_SMR_genes_all_update_text_500038",7/22/2024,Maya,,,,,,,,
Q45,What types of variants within RAB32 were found to have an effect on Parkinson's disease risk?,"There are no variants within the RAB32 gene found to have an effect on Parkinson's disease risk. Therefore, no distinct types of variants within RAB32 have been identified as influencing the risk of developing PD.","PDno23andme_full_gene_notext_7423787
PDno23andme_full_gene_notext_2174453
PDno23andme_full_gene_notext_6751603
PDno23andme_full_gene_notext_3299696
PDno23andme_full_gene_notext_3629191
PDno23andme_full_gene_notext_5519119
PDno23andme_full_gene_notext_2045193
PDno23andme_full_gene_notext_6502302
PDno23andme_full_gene_notext_3627818
PDno23andme_full_gene_notext_5668826
PDno23andme_full_gene_notext_5523003
PDno23andme_full_gene_notext_1674374
PDno23andme_full_gene_notext_2891370
PDno23andme_full_gene_notext_614411
PDno23andme_full_gene_notext_2576846
PDno23andme_full_gene_notext_739125
PDno23andme_full_gene_notext_5298852
PDno23andme_full_gene_notext_2898505",7/22/2024,Maya,,,,,,,,
Q46,Are there any association signals with the gene ADAM10 in Alzheimer's disease?,"Yes, there are three significant signals associated with the gene ADAM10 in Alzheimer's disease. 
•In the whole brain tissue the most significant SNP is rs2250583 with a multi SNP SMR p value of 2.60E-06 and a p-HEIDI of 0.07790174.
•In whole blood eQTL data the most significant SNP is rs7161799 and has a multi SNP SMR p value of 1.325576e-06 and a p-HEIDI value of 0.2374332.
•In the Cortex eQTL data the most significant SNP is rs1427280 which has a multi SNP SMR p value of 2.621155e-06 and a p-HEIDI value of 0.009769548.    ","NDD_SMR_genes_all_update_text_1500785
NDD_SMR_genes_all_update_text_105563
NDD_SMR_genes_all_update_text_1109990",7/22/2024,Maya,,,,,,,,
Q47,How do GBA gene mutations impact the risk of Parkinson's disease?,"Two GBA gene mutations were found to be significantly associated with an increased risk of Parkinson's disease: 
•rs12752133
P-value = 4.108e-29
b= 0.7821
•rs2230288
P-vlaue =3.055e-28
b= 0.7358","PDno23andme_full_gene_notext_7007839
PDno23andme_full_gene_notext_3083751",7/9/2024,Maya,,,,,,,,
Q48,What is the relevance of the gene TREM2 in Alzheimer's disease?,"The gene TREM2 is found to be significant in Alzheimer's disease within the cortex. Notably, the top associated snp is rs9394778, which has a p_SMR_multi of 6.308333e-07.",NDD_SMR_genes_all_update_text_1109138,7/22/2024,Maya,,,,,,,,
Q49,Is there a statistically significant association between any APOE SNPs and Alzheimer's Disease?,"Yes, the APOE gene is widely recognized as a major genetic risk factor for Alzheimer's Disease. Here are the 5 significantly associated SNPS:
•rs1081106
P-value= 7.203e-34
b= -0.2024
•rs769446
P-value= 4.229e-31
b= -0.1889
•rs769452
P-value= 7.494e-18
b= 0.7199
•rs769448
P-value= 7.81e-14
b= -0.2474
•rs439382
P-value= 2.933e-11
b= 0.9696
","AD_combo_gene_notext_UUID_19908970
AD_combo_gene_notext_UUID_19908949
AD_combo_gene_notext_UUID_19908960
AD_combo_gene_notext_UUID_19908952
AD_combo_gene_notext_UUID_19908948",7/9/2024,Maya,,,,,,,,
Q50,Is CCDC93 associated with AD in tibial nerves? ,"In eQTL omic data for the Tibial Nerve, the gene CCDC93, is not found to have a functionally significant role in Alzheimer's Disease.
• rs13429184
P-SMR Multi = 0.0455
P- Heidi = 0.640 

",NDD_SMR_genes_all_update_text_1285358,7/9/2024,Maya,,,,,,,,
Q51,"Based on blood_eQTLgen data, what is the top SNP in SNCA that is associated with Parkinson's disease (PD), and what is its p-value?","SNCA’s top associated SNP, is rs2245801, has a multi SNP SMR p value of 9.761195e-14 and a HEIDI value of 5.974436e-15.",NDD_SMR_genes_all_update_text_1555943,Jun 27,Marzieh,,,,,,,,
Q52,Has any relationship been reported between EIF2B3 and Alzheimer's Disease (AD)?,"No, based on the omic data from cortex, putamen basal ganglia, nucleus accumbens basal ganglia, whole blood, whole brain, and prefrontal cortex tissues, the gene EIF2B3 is not found to have a functionally significant role in Alzheimer's disease.","NDD_SMR_genes_all_update_text_1104733 NDD_SMR_genes_all_update_text_1582221 NDD_SMR_genes_all_update_text_1714909 NDD_SMR_genes_all_update_text_1490276 NDD_SMR_genes_all_update_text_37340 NDD_SMR_genes_all_update_text_37341  NDD_SMR_genes_all_update_text_1194963
 NDD_SMR_genes_all_update_text_37342 NDD_SMR_genes_all_update_text_1605096 NDD_SMR_genes_all_update_text_1244112 NDD_SMR_genes_all_update_text_652156 NDD_SMR_genes_all_update_text_1389059",6/27/2024 revised July 3th,Marzieh,,,,,,,,
Q53,What is the target of the drug Sontuzumab?,"The gene target of the drug Sontuzumab is MUC1 (mucin 1, cell surface associated).",DrugGeneTargets_text_11821,Jun 27,Marzieh/Maya,,,,,,,,
Q54,"What is the genetic target of the antibody drug Bectumomab, and what is its status in clinical trials and FDA approval?","The genetic target of the antibody drug Bectumomab is CD22 (CD22 molecule), which has the Ensembl identifier ENSG00000012124. Bectumomab reached phase 3 clinical trials but is not approved by the FDA for treatment of any disease.",DrugGeneTargets_text_10825,Jun 27,Marzieh,,,,,,,,
Q55,What are the synonymous names of the drug Flanvotumab?,"Flanvotumab has the associated synonyms 20-D-7S, 20D7S, IMC-20D7S, and IMC20D7S",DrugGeneTargets_text_12843,6/27/2024 revised July 3th,Marzieh,,,,,,,,
Q56,What are the genetic targets of the drug Naminidil?,"The genetic targets of the drug Naminidil are KCNJ11 (potassium inwardly rectifying channel subfamily J member 11), ABCC8 (ATP-binding cassette subfamily C member 8), ABCC9 (ATP-binding cassette subfamily C member 9), and KCNJ8 (potassium inwardly rectifying channel subfamily J member 8).",DrugGeneTargets_text_12141 DrugGeneTargets_text_12160  DrugGeneTargets_text_12672  DrugGeneTargets_text_12677,6/27/2024 revised July 3th,Marzieh/Maya,,,,,,,,
Q57,What are the genetic targets of the drug Halothane?,"Halothane has several genetic targets, such as KCNK2, KCNK9, KCNK18, KCNK10, KCNK3, GLRA1, GLRB, GABRA1, GABRB2, GABRG2, GABRB3, GABRA4, GABRG3, GABRQ, GABRA3, GABRP, GABRD, GABRG1, GABRB1, GABRE, GABRA2, GABRA5, and GABRA6","DrugGeneTargets_text_10053  DrugGeneTargets_text_10058 DrugGeneTargets_text_10065 DrugGeneTargets_text_10070
 DrugGeneTargets_text_10075 DrugGeneTargets_text_10082 DrugGeneTargets_text_10088 DrugGeneTargets_text_6712 DrugGeneTargets_text_6794 DrugGeneTargets_text_6872 DrugGeneTargets_text_6951 DrugGeneTargets_text_7030 DrugGeneTargets_text_7108 DrugGeneTargets_text_7184 DrugGeneTargets_text_7260 DrugGeneTargets_text_7340 DrugGeneTargets_text_7416 DrugGeneTargets_text_7492 DrugGeneTargets_text_7568 DrugGeneTargets_text_7649 DrugGeneTargets_text_7725 DrugGeneTargets_text_7806 DrugGeneTargets_text_7884",6/27/2024 revised July 3th,Marzieh,,,,,,,,
Q58,What is the maximum clinical trial phase for the drug Halothane?,Halothane reached phase 4 clinical trials.,"DrugGeneTargets_text_10053  DrugGeneTargets_text_10058 DrugGeneTargets_text_10065 DrugGeneTargets_text_10070
 DrugGeneTargets_text_10075 DrugGeneTargets_text_10082 DrugGeneTargets_text_10088 DrugGeneTargets_text_6712 DrugGeneTargets_text_6794 DrugGeneTargets_text_6872 DrugGeneTargets_text_6951 DrugGeneTargets_text_7030 DrugGeneTargets_text_7108 DrugGeneTargets_text_7184 DrugGeneTargets_text_7260 DrugGeneTargets_text_7340 DrugGeneTargets_text_7416 DrugGeneTargets_text_7492 DrugGeneTargets_text_7568 DrugGeneTargets_text_7649 DrugGeneTargets_text_7725 DrugGeneTargets_text_7806 DrugGeneTargets_text_7884",6/27/2024 revised July 3th,Marzieh,,,,,,,,
Q59,"When was Halothane first approved, and has it been withdrawn from use?",Halothane was first approved for use in 1958 and has not been withdrawn from use.,"DrugGeneTargets_text_10053  DrugGeneTargets_text_10058 DrugGeneTargets_text_10065 DrugGeneTargets_text_10070
 DrugGeneTargets_text_10075 DrugGeneTargets_text_10082 DrugGeneTargets_text_10088 DrugGeneTargets_text_6712 DrugGeneTargets_text_6794 DrugGeneTargets_text_6872 DrugGeneTargets_text_6951 DrugGeneTargets_text_7030 DrugGeneTargets_text_7108 DrugGeneTargets_text_7184 DrugGeneTargets_text_7260 DrugGeneTargets_text_7340 DrugGeneTargets_text_7416 DrugGeneTargets_text_7492 DrugGeneTargets_text_7568 DrugGeneTargets_text_7649 DrugGeneTargets_text_7725 DrugGeneTargets_text_7806 DrugGeneTargets_text_7884",6/27/2024 revised July 3th,Marzieh,,,,,,,,
Q60,"What type of molecule is Halothane, and what is its mechanism of action?","Halothane is a small molecule drug that acts as an opener, a positive allosteric modulator, and a positive modulator.","DrugGeneTargets_text_10053  DrugGeneTargets_text_10058 DrugGeneTargets_text_10065 DrugGeneTargets_text_10070
 DrugGeneTargets_text_10075 DrugGeneTargets_text_10082 DrugGeneTargets_text_10088 DrugGeneTargets_text_6712 DrugGeneTargets_text_6794 DrugGeneTargets_text_6872 DrugGeneTargets_text_6951 DrugGeneTargets_text_7030 DrugGeneTargets_text_7108 DrugGeneTargets_text_7184 DrugGeneTargets_text_7260 DrugGeneTargets_text_7340 DrugGeneTargets_text_7416 DrugGeneTargets_text_7492 DrugGeneTargets_text_7568 DrugGeneTargets_text_7649 DrugGeneTargets_text_7725 DrugGeneTargets_text_7806 DrugGeneTargets_text_7884",6/27/2024 revised July 3th,Marzieh,,,,,,,,
Q61,Is Halothane associated with any diseases?,"No, based on the data so far, Halothane is not associated with any diseases","DrugGeneTargets_text_10053  DrugGeneTargets_text_10058 DrugGeneTargets_text_10065 DrugGeneTargets_text_10070
 DrugGeneTargets_text_10075 DrugGeneTargets_text_10082 DrugGeneTargets_text_10088 DrugGeneTargets_text_6712 DrugGeneTargets_text_6794 DrugGeneTargets_text_6872 DrugGeneTargets_text_6951 DrugGeneTargets_text_7030 DrugGeneTargets_text_7108 DrugGeneTargets_text_7184 DrugGeneTargets_text_7260 DrugGeneTargets_text_7340 DrugGeneTargets_text_7416 DrugGeneTargets_text_7492 DrugGeneTargets_text_7568 DrugGeneTargets_text_7649 DrugGeneTargets_text_7725 DrugGeneTargets_text_7806 DrugGeneTargets_text_7884",6/27/2024 revised July 3th,Marzieh,,,,,,,,
Q62,"What is the top-associated SNP of the gene EMID2 in whole brain eQTL omic data for LBD disease, and is it significant?","The top-associated SNP for EMID2 in whole brain eQTL omic data for LBD disease is rs7805075, which has a multi-SNP SMR p-value of 0.8006395 and a HEIDI value of 0.7130096, and is not functionally significant.",NDD_SMR_genes_all_update_text_1629820,6/27/2024 revised July 3th,Marzieh,,,,,,,,
Q63,Is there any basal ganglia eQTL omic data available for the gene ZNF257 in relation to ALS (Amyotrophic Lateral Sclerosis) disease?,"Yes, there is Basal Ganglia eQTL omic data for the gene ZNF257, which indicates it does not have a functionally significant role in Amyotrophic Lateral Sclerosis.",NDD_SMR_genes_all_update_text_25257,6/27/2024 revised July 3th,Marzieh,,,,,,,,
Q64,What is the nearest gene to SNP rs12483639?,The nearest gene to SNP rs12483639 is APP.,PDno23andme_full_gene_notext_4687626,July 3th,Marzieh/Maya,,,,,,,,
Q65,What is the position of rs12483639 in GRCh37 and GRCh38?,The position of this SNP is 27442372 in GRCh37 and 26070056 in GRCh38.,PDno23andme_full_gene_notext_4687626,July 3th,Marzieh,,,,,,,,
Q66,"When was Fenfluramine approved for use, and has it been withdrawn or not?","Fenfluramine was first approved for use in 2020. Although it reached Phase 4 clinical trials and was approved, it has now been withdrawn from use.",DrugGeneTargets_text_1118 DrugGeneTargets_text_5806 DrugGeneTargets_text_10249,July 3th,Marzieh,,,,,,,,
Q67,When was Quazepam assigned a United States Adopted Name (USAN) and approved for use by the FDA?,Quazepam was assigned a USAN in 1976 and was approved for use by the FDA in 1985.,DrugTargetsIndication121923_text_964756 DrugTargetsIndication121923_text_964765 DrugTargetsIndication121923_text_964743 DrugTargetsIndication121923_text_964755 DrugTargetsIndication121923_text_964759 DrugTargetsIndication121923_text_964735 DrugTargetsIndication121923_text_964762 DrugTargetsIndication121923_text_964760 DrugTargetsIndication121923_text_964742 DrugTargetsIndication121923_text_964758 DrugTargetsIndication121923_text_964752 DrugTargetsIndication121923_text_964740 DrugTargetsIndication121923_text_964744 DrugTargetsIndication121923_text_964763 DrugTargetsIndication121923_text_964734 DrugTargetsIndication121923_text_964746 DrugTargetsIndication121923_text_964748 DrugTargetsIndication121923_text_964754 DrugTargetsIndication121923_text_964739 DrugTargetsIndication121923_text_964749 DrugTargetsIndication121923_text_964757 DrugTargetsIndication121923_text_964761 DrugTargetsIndication121923_text_964750 DrugTargetsIndication121923_text_964745 DrugTargetsIndication121923_text_964751 DrugTargetsIndication121923_text_964741 DrugTargetsIndication121923_text_964736 DrugTargetsIndication121923_text_964737 DrugTargetsIndication121923_text_964756 DrugTargetsIndication121923_text_964738 DrugTargetsIndication121923_text_964747 DrugTargetsIndication121923_text_964764,July 3th,Marzieh,,,,,,,,
Q68,"For what condition is Quazepam indicated, and which Experimental Factor Ontology (EFO) and Medical Subject Headings (MeSH) terms are associated with it?","Quazepam is indicated for the treatment of insomnia, associated with the Experimental Factor Ontology (EFO) term EFO:0004698 and the Medical Subject Headings (MeSH) term Sleep Initiation and Maintenance Disorders (D007319).",DrugTargetsIndication121923_text_964756 DrugTargetsIndication121923_text_964765 DrugTargetsIndication121923_text_964743 DrugTargetsIndication121923_text_964755 DrugTargetsIndication121923_text_964759 DrugTargetsIndication121923_text_964735 DrugTargetsIndication121923_text_964762 DrugTargetsIndication121923_text_964760 DrugTargetsIndication121923_text_964742 DrugTargetsIndication121923_text_964758 DrugTargetsIndication121923_text_964752 DrugTargetsIndication121923_text_964740 DrugTargetsIndication121923_text_964744 DrugTargetsIndication121923_text_964763 DrugTargetsIndication121923_text_964734 DrugTargetsIndication121923_text_964746 DrugTargetsIndication121923_text_964748 DrugTargetsIndication121923_text_964754 DrugTargetsIndication121923_text_964739 DrugTargetsIndication121923_text_964749 DrugTargetsIndication121923_text_964757 DrugTargetsIndication121923_text_964761 DrugTargetsIndication121923_text_964750 DrugTargetsIndication121923_text_964745 DrugTargetsIndication121923_text_964751 DrugTargetsIndication121923_text_964741 DrugTargetsIndication121923_text_964736 DrugTargetsIndication121923_text_964737 DrugTargetsIndication121923_text_964756 DrugTargetsIndication121923_text_964738 DrugTargetsIndication121923_text_964747 DrugTargetsIndication121923_text_964764,July 3th,Marzieh,,,,,,,,
Q69,What are the trade names and synonyms associated with Quazepam?,"The trade name of this drug is Doral, and its synonyms are NSC-309702, Quazepam, Quazepam civ, SCH 16134, and SCH-16134.",DrugTargetsIndication121923_text_964756 DrugTargetsIndication121923_text_964765 DrugTargetsIndication121923_text_964743 DrugTargetsIndication121923_text_964755 DrugTargetsIndication121923_text_964759 DrugTargetsIndication121923_text_964735 DrugTargetsIndication121923_text_964762 DrugTargetsIndication121923_text_964760 DrugTargetsIndication121923_text_964742 DrugTargetsIndication121923_text_964758 DrugTargetsIndication121923_text_964752 DrugTargetsIndication121923_text_964740 DrugTargetsIndication121923_text_964744 DrugTargetsIndication121923_text_964763 DrugTargetsIndication121923_text_964734 DrugTargetsIndication121923_text_964746 DrugTargetsIndication121923_text_964748 DrugTargetsIndication121923_text_964754 DrugTargetsIndication121923_text_964739 DrugTargetsIndication121923_text_964749 DrugTargetsIndication121923_text_964757 DrugTargetsIndication121923_text_964761 DrugTargetsIndication121923_text_964750 DrugTargetsIndication121923_text_964745 DrugTargetsIndication121923_text_964751 DrugTargetsIndication121923_text_964741 DrugTargetsIndication121923_text_964736 DrugTargetsIndication121923_text_964737 DrugTargetsIndication121923_text_964756 DrugTargetsIndication121923_text_964738 DrugTargetsIndication121923_text_964747 DrugTargetsIndication121923_text_964764,July 3th,Marzieh,,,,,,,,
Q70,Is Pritumumab approved by the FDA for the treatment of any disease?,"No, Pritumumab is not approved by the FDA for the treatment of any disease.",DrugGeneTargets_text_13746,July 3th,Marzieh,,,,,,,,
Q71,How many investigational indications does Iratumumab have?,Iratumumab has 3 investigational indications but is not approved by the FDA for the treatment of any disease.,DrugGeneTargets_text_13104,July 3th,Marzieh/Maya,,,,,,,,
Q72,When was Sonidegib Phosphate assigned a United States assigned name (USAN)?,Sonidegib Phosphate was assigned a United States assigned name (USAN) in 2013.,DrugTargetsIndication121923_text_1072620 DrugTargetsIndication121923_text_1072622 DrugTargetsIndication121923_text_1072621,July 3th,Marzieh,,,,,,,,
Q73,,,,,,,,,,,,,
Q74,,,,,,,,,,,,,
Q75,,,,,,,,,,,,,
Q76,,,,,,,,,,,,,
Q77,,,,,,,,,,,,,
Q78,,,,,,,,,,,,,
Q79,,,,,,,,,,,,,
Q80,,,,,,,,,,,,,
Q81,,,,,,,,,,,,,
Q82,,,,,,,,,,,,,
Q83,,,,,,,,,,,,,
Q84,,,,,,,,,,,,,
Q85,,,,,,,,,,,,,
Q86,,,,,,,,,,,,,
Q87,,,,,,,,,,,,,
Q88,,,,,,,,,,,,,
Q89,,,,,,,,,,,,,
Q90,,,,,,,,,,,,,
Q91,,,,,,,,,,,,,
Q92,,,,,,,,,,,,,
Q93,,,,,,,,,,,,,
Q94,,,,,,,,,,,,,
Q95,,,,,,,,,,,,,
Q96,,,,,,,,,,,,,
Q97,,,,,,,,,,,,,
Q98,,,,,,,,,,,,,
Q99,,,,,,,,,,,,,
Q100,,,,,,,,,,,,,
Q101,,,,,,,,,,,,,
Q102,,,,,,,,,,,,,
Q103,,,,,,,,,,,,,
Q104,,,,,,,,,,,,,
Q105,,,,,,,,,,,,,
Q106,,,,,,,,,,,,,
Q107,,,,,,,,,,,,,
Q108,,,,,,,,,,,,,
Q109,,,,,,,,,,,,,
Q110,,,,,,,,,,,,,
Q111,,,,,,,,,,,,,
Q112,,,,,,,,,,,,,
Q113,,,,,,,,,,,,,
Q114,,,,,,,,,,,,,
Q115,,,,,,,,,,,,,
Q116,,,,,,,,,,,,,
Q117,,,,,,,,,,,,,
Q118,,,,,,,,,,,,,
Q119,,,,,,,,,,,,,
Q120,,,,,,,,,,,,,
Q121,,,,,,,,,,,,,
Q122,,,,,,,,,,,,,
Q123,,,,,,,,,,,,,
Q124,,,,,,,,,,,,,
Q125,,,,,,,,,,,,,
Q126,,,,,,,,,,,,,
Q127,,,,,,,,,,,,,
Q128,,,,,,,,,,,,,
Q129,,,,,,,,,,,,,
Q130,,,,,,,,,,,,,
Q131,,,,,,,,,,,,,
Q132,,,,,,,,,,,,,
Q133,,,,,,,,,,,,,
Q134,,,,,,,,,,,,,
Q135,,,,,,,,,,,,,
Q136,,,,,,,,,,,,,
Q137,,,,,,,,,,,,,
Q138,,,,,,,,,,,,,
Q139,,,,,,,,,,,,,